Hallmarks of primary headache: part 1 - migraine.

GBD (2021) Nervous System Disorders Collaborators (2024) Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol 23:344–381

Stovner LJ, Hagen K, Linde M et al (2022) The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain 23:34

pubmed: 35410119 pmcid: 9004186 doi: 10.1186/s10194-022-01402-2

Dodick DW (2018) Migraine. Lancet 391:1315–1330

pubmed: 29523342 doi: 10.1016/S0140-6736(18)30478-1

Caponnetto V, Deodato M, Robotti M et al (2021) Comorbidities of primary headache disorders: a literature review with meta-analysis. J Headache Pain 22:71

pubmed: 34261435 pmcid: 8278743 doi: 10.1186/s10194-021-01281-z

Leonardi M, Raggi A (2019) A narrative review on the burden of migraine: when the burden is the impact on people’s life. J Headache Pain 20:41

pubmed: 31023226 pmcid: 6734273 doi: 10.1186/s10194-019-0993-0

Waliszewska-Prosół M, Montisano DA, Antolak M et al (2024) The impact of primary headaches on disability outcomes: a literature review and meta-analysis to inform future iterations of the Global Burden of Disease study. J Headache Pain 25:27

pubmed: 38433202 pmcid: 10910736 doi: 10.1186/s10194-024-01735-0

Martelletti P, Leonardi M, Ashina M et al (2023) Rethinking headache as a global public health case model for reaching the SDG 3 HEALTH by 2030. J Headache Pain 24:140

pubmed: 37884869 pmcid: 10604921 doi: 10.1186/s10194-023-01666-2

Steiner TJ, Husøy A, Thomas H et al (2023) The HARDSHIP databases: a forthcoming free good from the Global Campaign against Headache. J Headache Pain 24:21

pubmed: 36879195 pmcid: 9986863 doi: 10.1186/s10194-023-01554-9

Viana M, Khaliq F, Zecca C et al (2020) Poor patient awareness and frequent misdiagnosis of migraine: findings from a large transcontinental cohort. Eur J Neurol 27:536–541

pubmed: 31574197 doi: 10.1111/ene.14098

Caronna E, Gallardo VJ, Alpuente A et al (2022) Epidemiology, work and economic impact of migraine in a large hospital cohort: time to raise awareness and promote sustainability. J Neurol 269:1456–1462

pubmed: 34282471 doi: 10.1007/s00415-021-10715-2

Leonardi M, Martelletti P, Burstein R et al (2024) The World Health Organization Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders and the headache revolution: from headache burden to a global action plan for headache disorders. J Headache Pain 25:4

pubmed: 38178049 pmcid: 10768290 doi: 10.1186/s10194-023-01700-3

Tinelli M, Leonardi M, Paemeleire K et al (2021) Structured headache services as the solution to the ill-health burden of headache. 3. Modelling effectiveness and cost-effectiveness of implementation in Europe: findings and conclusions. J Headache Pain 22:90

pubmed: 34380429 pmcid: 8359596 doi: 10.1186/s10194-021-01305-8

Steiner TJ, Jensen R, Katsarava Z et al (2019) Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache. J Headache Pain 20:57

pubmed: 31113373 pmcid: 6734476 doi: 10.1186/s10194-018-0899-2

Pascual J, Panni T, Dell’Agnello G et al (2023) Preventive treatment patterns and treatment satisfaction in migraine: results of the OVERCOME (EU) study. J Headache Pain 24:88

pubmed: 37460942 pmcid: 10351193 doi: 10.1186/s10194-023-01623-z

Lampl C, MaassenVanDenBrink A, Deligianni CI et al (2023) The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis. J Headache Pain 24:56

pubmed: 37208596 pmcid: 10197489 doi: 10.1186/s10194-023-01594-1

Cheng YC, Zeng BY, Hung CM et al (2022) Effectiveness and acceptability of noninvasive brain and nerve stimulation techniques for migraine prophylaxis: a network meta-analysis of randomized controlled trials. J Headache Pain 23:28

pubmed: 35184742 pmcid: 8903676 doi: 10.1186/s10194-022-01401-3

Bae JY, Sung HK, Kwon NY et al (2021) Cognitive Behavioral Therapy for Migraine Headache: A Systematic Review and Meta-Analysis. Medicina (Kaunas) 58:44

pubmed: 35056352 doi: 10.3390/medicina58010044

Russell MB, Hilden J, Sørensen SA et al (1993) Olesen J. Familial occurrence of migraine without aura and migraine with aura. Neurology 43:1369–1373

pubmed: 8392151 doi: 10.1212/WNL.43.7.1369

Russell MB, Olesen J (1995) Increased familial risk and evidence of genetic factor in migraine. BMJ 311:541–544

pubmed: 7663209 pmcid: 2550605 doi: 10.1136/bmj.311.7004.541

Ophoff RA, Terwindt GM, Vergouwe MN et al (1996) Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 87:543–552

pubmed: 8898206 doi: 10.1016/S0092-8674(00)81373-2

Vanmolkot KR, Kors EE, Hottenga JJ et al (2003) Novel mutations in the Na+, K+-ATPase pump gene ATP1A2 associated with familial hemiplegic migraine and benign familial infantile convulsions. Ann Neurol 54:360–366

pubmed: 12953268 doi: 10.1002/ana.10674

Auffenberg E, Hedrich UB, Barbieri R et al (2021) Hyperexcitable interneurons trigger cortical spreading depression in an Scn1a migraine model. J Clin Invest 131:e142202

pubmed: 34546973 pmcid: 8553559 doi: 10.1172/JCI142202

Riant F, Roos C, Roubertie A et al (2022) Hemiplegic migraine associated with PRRT2 variations: a clinical and genetic study. Neurology 98:e51–e61

pubmed: 34649875 doi: 10.1212/WNL.0000000000012947

Adib-Samii P, Brice G, Martin RJ, Markus HS et al (2010) Clinical spectrum of CADASIL and the effect of cardiovascular risk factors on phenotype: study in 200 consecutively recruited individuals. Stroke 41:630–634

pubmed: 20167921 doi: 10.1161/STROKEAHA.109.568402

Hautakangas H, Winsvold BS, Ruotsalainen SE et al (2022) Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles. Nat Genet 54:152–160

pubmed: 35115687 pmcid: 8837554 doi: 10.1038/s41588-021-00990-0

Häppölä P, Gormley P, Nuottamo ME et al (2022) Polygenic risk provides biological validity for the ICHD-3 criteria among Finnish migraine families. Cephalalgia 42:345–356

pubmed: 34648375 doi: 10.1177/03331024211045651

Yang Y, Zhao H, Boomsma DI et al (2018) Molecular genetic overlap between migraine and major depressive disorder. Eur J Hum Genet 26:1202–1216

pubmed: 29995844 pmcid: 6057914 doi: 10.1038/s41431-018-0150-2

Guo Y, Rist PM, Daghlas I et al (2020) A genome-wide cross-phenotype meta-analysis of the association of blood pressure with migraine. Nat Commun 11:3368

pubmed: 32632093 pmcid: 7338361 doi: 10.1038/s41467-020-17002-0

Charles AC, Baca SM (2013) Cortical spreading depression and migraine. Nat Rev Neurol 9:637–644

pubmed: 24042483 doi: 10.1038/nrneurol.2013.192

Hiekkala ME, Vuola P, Artto V et al (2018) The contribution of CACNA1A, ATP1A2 and SCN1A mutations in hemiplegic migraine: a clinical and genetic study in Finnish migraine families. Cephalalgia 38:1849–1863

pubmed: 29486580 doi: 10.1177/0333102418761041

Russell MB, Ducros A (2011) Sporadic and familial hemiplegic migraine: pathophysiological mechanisms, clinical characteristics, diagnosis, and management. Lancet Neurol 10:457–470

pubmed: 21458376 doi: 10.1016/S1474-4422(11)70048-5

Lykke Thomsen L, Kirchmann Eriksen M, Faerch Romer S et al (2002) An epidemiological survey of hemiplegic migraine. Cephalalgia 22:361–375

pubmed: 12110112 doi: 10.1046/j.1468-2982.2002.00371.x

Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38:1–211

doi: 10.1177/0333102417738202

Thomsen LL, Olesen J, Russell MB (2003) Increased risk of migraine with typical aura in probands with familial hemiplegic migraine and their relatives. Eur J Neurol 10:421–427

pubmed: 12823495 doi: 10.1046/j.1468-1331.2003.00621.x

Friedrich T, Tavraz NN, Junghans C (2016) ATP1A2 Mutations in Migraine: Seeing through the Facets of an Ion Pump onto the Neurobiology of Disease. Front Physiol 7:239

pubmed: 27445835 pmcid: 4914835 doi: 10.3389/fphys.2016.00239

Guey S, Hervé D (2022) Main features of COL4A1-COL4A2 related cerebral microangiopathies. Cereb Circ Cogn Behav 3:100140

pubmed: 36324412 pmcid: 9616443

Wilms AE, de Boer I, Terwindt GM (2022) Retinal Vasculopathy with Cerebral Leukoencephalopathy and Systemic manifestations (RVCL-S): An update on basic science and clinical perspectives. Cereb Circ Cogn Behav 3:100046

pubmed: 36324396 pmcid: 9616387

Lafrenière RG, Cader MZ, Poulin JF et al (2010) A dominant-negative mutation in the TRESK potassium channel is linked to familial migraine with aura. Nat Med 16:1157–1160

pubmed: 20871611 doi: 10.1038/nm.2216

Brennan KC, Bates EA, Shapiro RE et al (2013) Casein kinase iδ mutations in familial migraine and advanced sleep phase. Sci Transl Med 5:183ra56, 1–11

pubmed: 23636092 doi: 10.1126/scitranslmed.3005784

Williams LB, Javed A, Sabri A et al (2019) ALPK1 missense pathogenic variant in five families leads to ROSAH syndrome, an ocular multisystem autosomal dominant disorder. Genet Med 21:2103–2115

pubmed: 30967659 pmcid: 6752478 doi: 10.1038/s41436-019-0476-3

Gormley P, Anttila V, Winsvold BS et al (2016) Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. Nat Genet 48:856–866

pubmed: 27322543 pmcid: 5331903 doi: 10.1038/ng.3598

Choquet H, Yin J, Jacobson AS et al (2021) New and sex-specific migraine susceptibility loci identified from a multiethnic genome-wide meta-analysis. Commun Biol 4:864

pubmed: 34294844 pmcid: 8298472 doi: 10.1038/s42003-021-02356-y

Gormley P, Kurki MI, Hiekkala ME et al (2018) Common variant burden contributes to the familial aggregation of migraine in 1,589 families. Neuron 98:743-753.e744

pubmed: 29731251 pmcid: 5967411 doi: 10.1016/j.neuron.2018.04.014

Malik R, Freilinger T, Winsvold BS et al (2015) Shared genetic basis for migraine and ischemic stroke: a genome-wide analysis of common variants. Neurology 84:2132–2145

pubmed: 25934857 pmcid: 4451048 doi: 10.1212/WNL.0000000000001606

Daghlas I, Guo Y, Chasman DI (2020) Effect of genetic liability to migraine on coronary artery disease and atrial fibrillation: a Mendelian randomization study. Eur J Neurol 27:550–556

pubmed: 31661179 doi: 10.1111/ene.14111

Daghlas I, Vgontzas A, Guo Y et al (2020) Habitual sleep disturbances and migraine: a Mendelian randomization study. Ann Clin Transl Neurol 7:2370–2380

pubmed: 33125193 pmcid: 7732254 doi: 10.1002/acn3.51228

Adewuyi EO, Sapkota Y, International Endogene Consortium Iec et al (2020) Shared molecular genetic mechanisms underlie endometriosis and migraine comorbidity. Genes (Basel) 11:268

pubmed: 32121467 doi: 10.3390/genes11030268

Kamm K (2022) CGRP and migraine: what have we learned from measuring CGRP in migraine patients so far? Front Neurol 13:930383

pubmed: 35968305 pmcid: 9363780 doi: 10.3389/fneur.2022.930383

Gallai V, Alberti A, Gallai B et al (2003) Glutamate and nitric oxide pathway in chronic daily headache: evidence from cerebrospinal fluid. Cephalalgia 23:166–174

pubmed: 12662182 doi: 10.1046/j.1468-2982.2003.00552.x

Lassen LH, Haderslev PA, Jacobsen VB et al (2002) CGRP may play a causative role in migraine. Cephalalgia 22:54–61

pubmed: 11993614 doi: 10.1046/j.1468-2982.2002.00310.x

Eftekhari S, Warfvinge K, Blixt FW et al (2013) Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. J Pain 14:1289–1303

pubmed: 23958278 doi: 10.1016/j.jpain.2013.03.010

De Logu F, Nassini R, Hegron A et al (2022) Schwann cell endosome CGRP signals elicit periorbital mechanical allodynia in mice. Nat Commun 13:646

pubmed: 35115501 pmcid: 8813987 doi: 10.1038/s41467-022-28204-z

Rees TA, Labastida-Ramírez A, Rubio-Beltrán E (2023) Calcitonin/PAC1 receptor splice variants: a blind spot in migraine research. Trends Pharmacol Sci 44:651–663

pubmed: 37543479 pmcid: 10529278 doi: 10.1016/j.tips.2023.07.003

Edvinsson L (2017) The Trigeminovascular Pathway: Role of CGRP and CGRP Receptors in Migraine. Headache 57(Suppl 2):47–55

pubmed: 28485848 doi: 10.1111/head.13081

Kilinc E, Guerrero-Toro C, Zakharov A et al (2017) Serotonergic mechanisms of trigeminal meningeal nociception: Implications for migraine pain. Neuropharmacology 116:160–173

pubmed: 28025094 doi: 10.1016/j.neuropharm.2016.12.024

Della Pietra A, Gómez Dabó L, Mikulenka P et al (2024) Mechanosensitive receptors in migraine: a systematic review. J Headache Pain 25:6

pubmed: 38221631 pmcid: 10788982 doi: 10.1186/s10194-023-01710-1

Ghanizada H, Al-Karagholi MA, Walker CS et al (2021) Amylin analog pramlintide induces migraine-like attacks in patients. Ann Neurol 89:1157–1171

pubmed: 33772845 pmcid: 8486152 doi: 10.1002/ana.26072

Labastida-Ramírez A, Runio-Beltran E, Holland PR, et al. (2024) Sexually dimorphic effects of Amylin 1 receptor activation in trigeminovascular neurons. bioRxiv. 2024.01.12.575235. https://doi.org/10.1101/2024.01.12.575235

Rees TA, Russo AF, O’Carroll SJ et al (2022) CGRP and the calcitonin receptor are co-expressed in mouse, rat and human trigeminal ganglia neurons. Front Physiol 13:860037

pubmed: 35620595 pmcid: 9128745 doi: 10.3389/fphys.2022.860037

Al-Karagholi MA (2023) Involvement of potassium channel signalling in migraine pathophysiology. Pharmaceuticals (Basel) 16:438

pubmed: 36986537 doi: 10.3390/ph16030438

Fahrenkrug J, Goetzl EJ, Gozes I, et al (2023) VIP and PACAP receptors in GtoPdb v.2023.1. Available from: https://journals.ed.ac.uk/gtopdb-cite/article/view/8714 . Accessed 12 July 2024

Harmar AJ, Fahrenkrug J, Gozes I et al (2012) Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br J Pharmacol 166:4–17

pubmed: 22289055 pmcid: 3415633 doi: 10.1111/j.1476-5381.2012.01871.x

Schytz HW, Birk S, Wienecke T et al (2009) PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 132:16–25

pubmed: 19052139 doi: 10.1093/brain/awn307

Ghanizada H, Al-Karagholi MA, Arngrim N et al (2020) PACAP27 induces migraine-like attacks in migraine patients. Cephalalgia 40:57–67

pubmed: 31299857 doi: 10.1177/0333102419864507

Rubio-Beltrán E, Correnti E, Deen M et al (2018) PACAP38 and PAC1 receptor blockade: a new target for headache? J Headache Pain 19:64

pubmed: 30088106 pmcid: 6081277 doi: 10.1186/s10194-018-0893-8

Tasma Z, Siow A, Harris PWR et al (2022) Characterisation of agonist signalling profiles and agonist-dependent antagonism at PACAP-responsive receptors: Implications for drug discovery. Br J Pharmacol 179:435–453

pubmed: 34612509 doi: 10.1111/bph.15700

Olesen J (2024) Provocation of attacks to discover migraine signaling mechanisms and new drug targets: early history and future perspectives - a narrative review. J Headache Pain 25:105

pubmed: 38902612 pmcid: 11188241 doi: 10.1186/s10194-024-01796-1

Christiansen I, Thomsen LL, Daugaard D et al (1999) Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura. Cephalalgia 19:660–667

pubmed: 10524660 doi: 10.1046/j.1468-2982.1999.019007660.x

Lassen LH, Ashina M, Christiansen I et al (1997) Nitric oxide synthase inhibition in migraine. Lancet 349:401–402

pubmed: 9033475 doi: 10.1016/S0140-6736(97)80021-9

Birk S, Kruuse C, Petersen KA et al (2004) The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow. J Cereb Blood Flow Metab 24:1352–1358

pubmed: 15625409 doi: 10.1097/01.WCB.0000143536.22131.D7

Schankin CJ, Kruse LS, Reinisch VM et al (2010) Nitric oxide-induced changes in endothelial expression of phosphodiesterases 2, 3, and 5. Headache 50:431–441

pubmed: 19751368 doi: 10.1111/j.1526-4610.2009.01512.x

Nordgaard JC, Kruse LS, Møller M et al (2014) Phosphodiesterases 3 and 5 express activity in the trigeminal ganglion and co-localize with calcitonin gene-related peptide. Cephalalgia 34:503–513

pubmed: 24322481 doi: 10.1177/0333102413515345

Guo S, Olesen J, Ashina M (2014) Phosphodiesterase 3 inhibitor cilostazol induces migraine-like attacks via cyclic AMP increase. Brain 137:2951–2959

pubmed: 25161294 doi: 10.1093/brain/awu244

Falkenberg K, Bjerg HR, Olesen J (2020) Subcutaneous sumatriptan reduces cilostazol induced headache in migraine patients. Cephalalgia 40:842–850

pubmed: 32216457 doi: 10.1177/0333102420915166

Younis S, Christensen CE, Toft NM et al (2019) Investigation of distinct molecular pathways in migraine induction using calcitonin gene-related peptide and sildenafil. Cephalalgia 39:1776–1788

pubmed: 31684759 doi: 10.1177/0333102419882474

Raffaelli B, Do TP, Ashina H et al (2024) Induction of cGMP-mediated migraine attacks is independent of CGRP receptor activation. Cephalalgia 44:3331024241259489

pubmed: 38850034 doi: 10.1177/03331024241259489

Silvestro M, Iannone LF, Orologio I et al (2023) Migraine Treatment: Towards New Pharmacological Targets. Int J Mol Sci 24:12268

pubmed: 37569648 pmcid: 10418850 doi: 10.3390/ijms241512268

Shyng S, Nichols CG (1997) Octameric stoichiometry of the KATP channel complex. J Gen Physiol 110:655–664

pubmed: 9382894 pmcid: 2229396 doi: 10.1085/jgp.110.6.655

Kokoti L, Al-Karagholi MA, Zhuang ZA et al (2024) Non-vascular ATP-sensitive potassium channel activation does not trigger migraine attacks: a randomized clinical trial. Cephalalgia 44:3331024241248211

pubmed: 38729773 doi: 10.1177/03331024241248211

Dyhring T, Jansen-Olesen I, Christophersen P et al (2023) Pharmacological profiling of KATP channel modulators: an outlook for new treatment opportunities for migraine. Pharmaceuticals (Basel) 16:225

pubmed: 37259373 doi: 10.3390/ph16020225

Al-Karagholi MA, Ghanizada H, Nielsen CAW et al (2021) Opening of ATP sensitive potassium channels causes migraine attacks with aura. Brain 144:2322–2332

pubmed: 33768245 doi: 10.1093/brain/awab136

Al-Karagholi MA, Hansen JM, Guo S et al (2019) Opening of ATP-sensitive potassium channels causes migraine attacks: a new target for the treatment of migraine. Brain 142:2644–2654

pubmed: 31292608 doi: 10.1093/brain/awz199

Al-Karagholi MA, Ghanizada H, Waldorff Nielsen CA et al (2021) Opening of BKCa channels causes migraine attacks: a new downstream target for the treatment of migraine. Pain 162:2512–2520

pubmed: 34252916 doi: 10.1097/j.pain.0000000000002238

Labastida-Ramírez A, Rubio-Beltrán E, Haanes KA et al (2020) Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system. Pain 161:1092–1099

pubmed: 31977930 pmcid: 7170441 doi: 10.1097/j.pain.0000000000001801

Classey JD, Bartsch T, Goadsby PJ (2010) Distribution of 5-HT(1B), 5-HT(1D) and 5-HT(1F) receptor expression in rat trigeminal and dorsal root ganglia neurons: relevance to the selective anti-migraine effect of triptans. Brain Res 1361:76–85

pubmed: 20833155 doi: 10.1016/j.brainres.2010.09.004

Iannone LF, De Logu F, Geppetti P et al (2022) The role of TRP ion channels in migraine and headache. Neurosci Lett 768:136380

pubmed: 34861342 doi: 10.1016/j.neulet.2021.136380

Messina R, Cetta I, Colombo B et al (2022) Tracking the evolution of non-headache symptoms through the migraine attack. J Headache Pain 23:149

pubmed: 36418943 pmcid: 9686019 doi: 10.1186/s10194-022-01525-6

Dodick DW (2018) A phase-by-phase review of migraine pathophysiology. Headache 58(Suppl 1):4–16

pubmed: 29697154 doi: 10.1111/head.13300

Vincent M, Viktrup L, Nicholson RA et al (2022) The not so hidden impact of interictal burden in migraine: a narrative review. Front Neurol 13:1032103

pubmed: 36408525 pmcid: 9669578 doi: 10.3389/fneur.2022.1032103

Gago-Veiga AB, Vivancos J, Sobrado M (2021) The premonitory phase: A crucial stage in migraine. Neurologia (Engl Ed) 36:298–304

pubmed: 29277522 doi: 10.1016/j.nrl.2017.09.014

Eigenbrodt AK, Christensen RH, Ashina H et al (2022) Premonitory symptoms in migraine: a systematic review and meta-analysis of observational studies reporting prevalence or relative frequency. J Headache Pain 23:140

pubmed: 36371152 doi: 10.1186/s10194-022-01510-z

Karsan N, Goadsby PJ (2023) Neuroimaging in the pre-ictal or premonitory phase of migraine: a narrative review. J Headache Pain 24:106

pubmed: 37563570 doi: 10.1186/s10194-023-01617-x

Lipton RB, Lanteri-Minet M, Leroux E et al (2023) Pre- and post-headache phases of migraine: multi-country results from the CaMEO - International Study. J Headache Pain 24:151

pubmed: 37940856 doi: 10.1186/s10194-023-01683-1

May A (2017) Understanding migraine as a cycling brain syndrome: reviewing the evidence from functional imaging. Neurol Sci 38(Suppl 1):125–130

pubmed: 28527054 doi: 10.1007/s10072-017-2866-0

Lauritzen M (1994) Pathophysiology of the migraine aura. The spreading depression theory. Brain 117:199–210

pubmed: 7908596 doi: 10.1093/brain/117.1.199

Hadjikhani N, Sanchez Del Rio M, Wu O et al (2001) Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci U S A 98:4687–4692

pubmed: 11287655 doi: 10.1073/pnas.071582498

Lee MJ, Park BY, Cho S et al (2019) Dynamic functional connectivity of the migraine brain: a resting-state functional magnetic resonance imaging study. Pain 160:2776–2786

pubmed: 31408050 doi: 10.1097/j.pain.0000000000001676

Karatas H, Erdener SE, Gursoy-Ozdemir Y et al (2013) Spreading depression triggers headache by activating neuronal Panx1 channels. Science 339:1092–1095

pubmed: 23449592 doi: 10.1126/science.1231897

Noseda R, Burstein R (2013) Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain. Pain 154(Suppl 1):S44-53

pubmed: 23891892 doi: 10.1016/j.pain.2013.07.021

Pietrobon D, Moskowitz MA (2013) Pathophysiology of migraine. Annu Rev Physiol 75:365–391

pubmed: 23190076 doi: 10.1146/annurev-physiol-030212-183717

Vila-Pueyo M, Hoffmann J, Romero-Reyes M et al (2019) Brain structure and function related to headache: Brainstem structure and function in headache. Cephalalgia 39:1635–1660

pubmed: 29969040 doi: 10.1177/0333102418784698

Christensen RH, Eigenbrodt AK, Ashina H et al (2023) What proportion of people with migraine report postdromal symptoms? A systematic review and meta-analysis of observational studies. Cephalalgia 43:3331024231206376

pubmed: 37851650 doi: 10.1177/03331024231206376

Thuraiaiyah J, Ashina H, Christensen RH et al (2024) Postdromal symptoms in migraine: a REFORM study. J Headache Pain 25:25

pubmed: 38383318 pmcid: 10880332 doi: 10.1186/s10194-024-01716-3

Brighina F, Cosentino G, Fierro B (2016) Habituation or lack of habituation: What is really lacking in migraine? Clin Neurophysiol 127:19–20

pubmed: 26089233 doi: 10.1016/j.clinph.2015.05.028

Di Antonio S, Castaldo M, Ponzano M et al (2021) Disability, burden, and symptoms related to sensitization in migraine patients associate with headache frequency. Scand J Pain 21:766–777

pubmed: 34253003 doi: 10.1515/sjpain-2021-0050

Han SM, Kim KM, Cho SJ et al (2021) Prevalence and characteristics of cutaneous allodynia in probable migraine. Sci Rep 11:2467

pubmed: 33510340 pmcid: 7844001 doi: 10.1038/s41598-021-82080-z

Coppola G, Parisi V, Di Renzo A et al (2020) Cortical pain processing in migraine. J Neural Transm (Vienna) 127:551–566

pubmed: 31598777 doi: 10.1007/s00702-019-02089-7

Aguggia M, Saracco MG, Cavallini M et al (2013) Sensitization and pain. Neurol Sci 34(Suppl 1):S37-40

pubmed: 23695043 doi: 10.1007/s10072-013-1382-0

Burstein R, Jakubowski M, Garcia-Nicas E et al (2010) Thalamic sensitization transforms localized pain into widespread allodynia. Ann Neurol 68:81–91

pubmed: 20582997 pmcid: 2930514 doi: 10.1002/ana.21994

Martinelli D, Pocora MM, De Icco R et al (2022) Triggers of migraine: where do we stand? Curr Opin Neurol 35:360–366

pubmed: 35674080 doi: 10.1097/WCO.0000000000001065

Fischer-Schulte LH (2023) Peng KP (2023) Migraine prodromes and migraine triggers. Handb Clin Neurol 198:135–148

pubmed: 38043958 doi: 10.1016/B978-0-12-823356-6.00014-7

Russo A, Tessitore A, Silvestro M et al (2019) Advanced visual network and cerebellar hyperresponsiveness to trigeminal nociception in migraine with aura. J Headache Pain 20:46

pubmed: 31053057 doi: 10.1186/s10194-019-1002-3

Burke MJ, Joutsa J, Cohen AL et al (2020) Mapping migraine to a common brain network. Brain 143:541–553

pubmed: 31919494 doi: 10.1093/brain/awz405

Hadjikhani N, Del Rio MS, Wu O et al (2001) Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci 98:4687–4692

pubmed: 11287655 doi: 10.1073/pnas.071582498

Maniyar FH, Sprenger T, Schankin C et al (2014) Photic hypersensitivity in the premonitory phase of migraine – a positron emission tomography study. Eur J Neurol 21:1178–1183

pubmed: 24780052 doi: 10.1111/ene.12451

Puledda F, Ffytche D, O’Daly O et al (2019) Imaging the Visual Network in the Migraine Spectrum. Front Neurol 10:1325

pubmed: 31920945 doi: 10.3389/fneur.2019.01325

Schulte LH, May A (2016) The migraine generator revisited: continuous scanning of the migraine cycle over 30 days and three spontaneous attacks. Brain 139:1987–1993

pubmed: 27190019 doi: 10.1093/brain/aww097

Schulte LH, Mehnert J, May A (2020) Longitudinal neuroimaging over 30 days: temporal characteristics of migraine. Ann Neurol 87:646–651

pubmed: 32031707 doi: 10.1002/ana.25697

Schwedt TJ, Chiang C-C, Chong CD et al (2015) Functional MRI of migraine. Lancet Neurol 14:81–91

pubmed: 25496899 doi: 10.1016/S1474-4422(14)70193-0

Moulton EA, Becerra L, Maleki N et al (2011) Painful heat reveals hyperexcitability of the temporal pole in interictal and ictal migraine States. Cereb Cortex 21:435–448

pubmed: 20562317 doi: 10.1093/cercor/bhq109

Schwedt TJ, Chong CD, Chiang CC et al (2014) Enhanced pain-induced activity of pain-processing regions in a case-control study of episodic migraine. Cephalalgia 34:947–958

pubmed: 24627432 doi: 10.1177/0333102414526069

Kim JH, Kim S, Suh S-I et al (2010) Interictal metabolic changes in episodic migraine: a voxel-based FDG-PET study. Cephalalgia 30:53–61

pubmed: 19489887 doi: 10.1111/j.1468-2982.2009.01890.x

Tessitore A, Russo A, Conte F et al (2015) Abnormal connectivity within executive resting-state network in migraine with aura. Headache 55:794–805

pubmed: 26084236 doi: 10.1111/head.12587

Chong CD, Gaw N, Fu Y et al (2017) Migraine classification using magnetic resonance imaging resting-state functional connectivity data. Cephalalgia 37:828–844

pubmed: 27306407 doi: 10.1177/0333102416652091

Szabo N, Kincses ZT, Párdutz Á et al (2012) White matter microstructural alterations in migraine: a diffusion-weighted MRI study. Pain 153:651–656

pubmed: 22244439 doi: 10.1016/j.pain.2011.11.029

Amin FM, Hougaard A, Magon S et al (2016) Change in brain network connectivity during PACAP38-induced migraine attacks: a resting-state functional MRI study. Neurology 86:180–187

pubmed: 26674334 doi: 10.1212/WNL.0000000000002261

Ellingson BM, Hesterman C, Johnston M et al (2019) Advanced imaging in the evaluation of migraine headaches. Neuroimaging Clin N Am 29:301–324

pubmed: 30926119 doi: 10.1016/j.nic.2019.01.009

Karsan N, Silva E, Goadsby PJ (2023) Evaluating migraine with typical aura with neuroimaging. Front Hum Neurosci 17:1112790

pubmed: 37025972 doi: 10.3389/fnhum.2023.1112790

Gaist D, Hougaard A, Garde E et al (2018) Migraine with visual aura associated with thicker visual cortex. Brain 141:776–785

pubmed: 29360944 doi: 10.1093/brain/awx382

Bridge H, Stagg CJ, Near J et al (2015) Altered neurochemical coupling in the occipital cortex in migraine with visual aura. Cephalalgia 35:1025–1030

pubmed: 25631169 doi: 10.1177/0333102414566860

Tedeschi G, Russo A, Conte F et al (2016) Increased interictal visual network connectivity in patients with migraine with aura. Cephalalgia 36:139–147

pubmed: 25926619 doi: 10.1177/0333102415584360

Datta R, Aguirre GK, Hu S et al (2013) Interictal cortical hyperresponsiveness in migraine is directly related to the presence of aura. Cephalalgia 33:365–374

pubmed: 23359872 doi: 10.1177/0333102412474503

Faragó P, Tóth E, Kocsis K et al (2019) Altered resting state functional activity and microstructure of the white matter in migraine with aura. Front Neurol 10:1039

pubmed: 31632336 doi: 10.3389/fneur.2019.01039

Hougaard A, Amin F, Larsson H et al (2017) Increased intrinsic brain connectivity between pons and somatosensory cortex during attacks of migraine with aura. Hum Brain Mapp 38:2635–2642

pubmed: 28240389 doi: 10.1002/hbm.23548

Coppola G, Corbelli I, Di Renzo A et al (2022) Visual stimulation and frequency of focal neurological symptoms engage distinctive neurocognitive resources in migraine with aura patients: a study of resting-state functional networks. J Headache Pain 23:80

pubmed: 35820799 doi: 10.1186/s10194-022-01446-4

Lauritzen M, Olsen TS, Lassen NA et al (1983) Changes in regional cerebral blood flow during the course of classic migraine attacks. Ann Neurol 13:633–641

pubmed: 6881926 doi: 10.1002/ana.410130609

Fu T, Liu L, Huang X et al (2022) Cerebral blood flow alterations in migraine patients with and without aura: an arterial spin labeling study. J Headache Pain 23:131

pubmed: 36195842 pmcid: 9531478 doi: 10.1186/s10194-022-01501-0

Christensen RH, Gollion C, Amin FM et al (2022) Imaging the inflammatory phenotype in migraine. J Headache Pain 23:60

pubmed: 35650524 pmcid: 9158262 doi: 10.1186/s10194-022-01430-y

Silvestro M, Tessitore A, Di Nardo F et al (2022) Functional connectivity changes in complex migraine aura: beyond the visual network. Eur J Neurol 29:295–304

pubmed: 34382315 doi: 10.1111/ene.15061

Petrusic I, Viana M, Dakovic M et al (2019) Application of the migraine aura complexity score (MACS): clinical and neuroimaging study. Front Neurol 10:1112

pubmed: 31681162 pmcid: 6813918 doi: 10.3389/fneur.2019.01112

Coppola G, Di Renzo A, Tinelli E et al (2021) Thalamo-cortical networks in subtypes of migraine with aura patients. J Headache Pain 22:58

pubmed: 34147064 pmcid: 8214259 doi: 10.1186/s10194-021-01272-0

Abagnale C, Di Renzo A, Sebastianelli G et al (2023) Whole brain surface-based morphometry and tract-based spatial statistics in migraine with aura patients: difference between pure visual and complex auras. Front Hum Neurosci 17:1146302

pubmed: 37144161 doi: 10.3389/fnhum.2023.1146302

Mitrović K, Petrušić I, Radojičić A et al (2023) Migraine with aura detection and subtype classification using machine learning algorithms and morphometric magnetic resonance imaging data. Front Neurol 14:1106612

pubmed: 37441607 doi: 10.3389/fneur.2023.1106612

Mitrović K, Savić AM, Radojičić A (2023) Machine learning approach for Migraine Aura Complexity Score prediction based on magnetic resonance imaging data. J Headache Pain 24:169

pubmed: 38105182 doi: 10.1186/s10194-023-01704-z

Lee MJ, Park BY, Cho S et al (2019) Increased connectivity of pain matrix in chronic migraine: a resting-state functional MRI study. J Headache Pain 20:29

pubmed: 30909865 doi: 10.1186/s10194-019-0986-z

Coppola G, Petolicchio B, Di Renzo A et al (2017) Cerebral gray matter volume in patients with chronic migraine: correlations with clinical features. J Headache Pain 18:115

pubmed: 29322264 doi: 10.1186/s10194-017-0825-z

Lai TH, Chou KH, Fuh JL et al (2016) Gray matter changes related to medication overuse in patients with chronic migraine. Cephalalgia 36:1324–1333

pubmed: 26853805 doi: 10.1177/0333102416630593

Li X, Liu M, Fan W et al (2023) Altered cerebral neurovascular coupling in medication-overuse headache: a study combining multi-modal resting-state fMRI with 3D PCASL. Front Neurosci 17:1139086

pubmed: 37008219 doi: 10.3389/fnins.2023.1139086

Russo A, Coppola G, Pierelli F et al (2018) Pain perception and migraine. Front Neurol 9:576

pubmed: 30116215 doi: 10.3389/fneur.2018.00576

Sandrini G, Rossi P, Milanov I et al (2006) Abnormal modulatory influence of diffuse noxious inhibitory controls in migraine and chronic tension-type headache patients. Cephalalgia 26:782–789

pubmed: 16776692 doi: 10.1111/j.1468-2982.2006.01130.x

Morrison DP (1990) Abnormal perceptual experiences in migraine. Cephalalgia 10:273–277

pubmed: 2289227 doi: 10.1046/j.1468-2982.1990.1006273.x

Shechter A, Stewart WF, Silberstein SD et al (2002) Migraine and autonomic nervous system function: a population-based, case-control study. Neurology 58:422–427

pubmed: 11839842 doi: 10.1212/WNL.58.3.422

Koenig J, Williams DP, Kemp AH et al (2016) Vagally mediated heart rate variability in headache patients–a systematic review and meta-analysis. Cephalalgia 36:265–278

pubmed: 25962595 doi: 10.1177/0333102415583989

Chuang CH, Li JY, King JT et al (2023) Abnormal heart rate variability and its application in predicting treatment efficacy in patients with chronic migraine: an exploratory study. Cephalalgia 43:3331024231206781

pubmed: 37851663 doi: 10.1177/03331024231206781

Hvedstrup J, Kolding LT, Ashina M et al (2020) Increased neck muscle stiffness in migraine patients with ictal neck pain: a shear wave elastography study. Cephalalgia 40:565–574

pubmed: 32295400 doi: 10.1177/0333102420919998

Do TP, Heldarskard GF, Kolding LT et al (2018) Myofascial trigger points in migraine and tension-type headache. J Headache Pain 19:84

pubmed: 30203398 pmcid: 6134706 doi: 10.1186/s10194-018-0913-8

Leistad RB, Sand T, Westgaard RH et al (2006) Stress-induced pain and muscle activity in patients with migraine and tension-type headache. Cephalalgia 26:64–73

pubmed: 16396668 doi: 10.1111/j.1468-2982.2005.00997.x

Luedtke K, Mehnert J, May A (2018) Altered muscle activity during rest and during mental or physical activity is not a trait symptom of migraine - a neck muscle EMG study. J Headache Pain 19:26

pubmed: 29556874 pmcid: 5859002 doi: 10.1186/s10194-018-0851-5

Zhang X, Levy D, Kainz V et al (2011) Activation of central trigeminovascular neurons by cortical spreading depression. Ann Neurol 69:855–865

pubmed: 21416489 pmcid: 3174689 doi: 10.1002/ana.22329

Costa C, Tozzi A, Rainero I et al (2013) Cortical spreading depression as a target for anti-migraine agents. J Headache Pain 14:62

pubmed: 23879550 pmcid: 3728002 doi: 10.1186/1129-2377-14-62

Coppola G, Di Lorenzo C, Schoenen J et al (2013) Habituation and sensitization in primary headaches. J Headache Pain 14:65

pubmed: 23899115 pmcid: 3733593 doi: 10.1186/1129-2377-14-65

Coppola G, Pierelli F, Schoenen J (2009) Habituation and migraine. Neurobiol Learn Mem 92:249–259

pubmed: 18675928 doi: 10.1016/j.nlm.2008.07.006

Chen WT, Hsiao FJ, Ko YC et al (2018) Comparison of somatosensory cortex excitability between migraine and “strict-criteria” tension-type headache: a magnetoencephalographic study. Pain 159:793–803

pubmed: 29319611 doi: 10.1097/j.pain.0000000000001151

Abagnale C, Ranieri F, Di Renzo A et al (2021) Impaired short-term visual paired associative plasticity in patients with migraine between attacks. Pain 162:803–810

pubmed: 33136981 doi: 10.1097/j.pain.0000000000002085

Puledda F, Vigano A, Sebastianelli G et al (2023) Electrophysiological findings in migraine may reflect abnormal synaptic plasticity mechanisms: a narrative review. Cephalalgia 43:3331024231195780

pubmed: 37622421 doi: 10.1177/03331024231195780

Hsiao FJ, Chen WT, Liu HY et al (2021) Migraine chronification is associated with beta-band connectivity within the pain-related cortical regions: a magnetoencephalographic study. Pain 162:2590–2598

pubmed: 34534180 doi: 10.1097/j.pain.0000000000002255

Hsiao FJ, Chen WT, Pan LH et al (2022) Resting-state magnetoencephalographic oscillatory connectivity to identify patients with chronic migraine using machine learning. J Headache Pain 23:130

pubmed: 36192689 pmcid: 9531441 doi: 10.1186/s10194-022-01500-1

Hsiao FJ, Chen WT, Wu YT et al (2023) Characteristic oscillatory brain networks for predicting patients with chronic migraine. J Headache Pain 24:139

pubmed: 37848845 pmcid: 10583316 doi: 10.1186/s10194-023-01677-z

Tessitore A, Russo A, Giordano A et al (2013) Disrupted default mode network connectivity in migraine without aura. J Headache Pain 14:89

pubmed: 24207164 pmcid: 3832236 doi: 10.1186/1129-2377-14-89

Skorobogatykh K, van Hoogstraten WS, Degan D et al (2019) Functional connectivity studies in migraine: what have we learned? J Headache Pain 20:108

pubmed: 31747874 pmcid: 6868768 doi: 10.1186/s10194-019-1047-3

Schramm S, Borner C, Reichert M et al (2023) Functional magnetic resonance imaging in migraine: a systematic review. Cephalalgia 43:3331024221128278

pubmed: 36751858 doi: 10.1177/03331024221128278

Porcaro C, Di Lorenzo G, Seri S et al (2017) Impaired brainstem and thalamic high-frequency oscillatory EEG activity in migraine between attacks. Cephalalgia 37:915–926

pubmed: 27358281 doi: 10.1177/0333102416657146

Hsiao FJ, Chen WT, Pan LH et al (2022) Dynamic brainstem and somatosensory cortical excitability during migraine cycles. J Headache Pain 23:21

pubmed: 35123411 pmcid: 8903675 doi: 10.1186/s10194-022-01392-1

GBD (2016) Nervous System Disorders Collaborators (2019) Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18:459–480

GBD (2019) Nervous System Disorders Collaborators (2020) Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396:1204–1222

Rosignoli C, Ornello R, Onofri A et al (2022) Applying a biopsychosocial model to migraine: rationale and clinical implications. J Headache Pain 23:100

pubmed: 35953769 doi: 10.1186/s10194-022-01471-3

Eigenbrodt AK, Ashina H, Khan S et al (2021) Diagnosis and management of migraine in ten steps. Nat Revi Neurol 17:501–514

doi: 10.1038/s41582-021-00509-5

Leppert MH, Poisson SN, Scarbro S et al (2024) Association of traditional and nontraditional risk factors in the development of strokes among young adults by sex and age group: a retrospective case-control study. Circ Cardiovasc Qual Outcomes 17:e010307

pubmed: 38529631 doi: 10.1161/CIRCOUTCOMES.123.010307

Kurth T, Chabriat H, Bousser MG (2012) Migraine and stroke: a complex association with clinical implications. Lancet Neurol 11:92–100

pubmed: 22172624 doi: 10.1016/S1474-4422(11)70266-6

Kruit MC, Launer LJ, Ferrari MD et al (2005) Infarcts in the posterior circulation territory in migraine. The population-based MRI CAMERA study. Brain 128:2068–2077

pubmed: 16006538 doi: 10.1093/brain/awh542

Kruit MC, van Buchem MA, Hofman PA et al (2004) Migraine as a risk factor for subclinical brain lesions. JAMA 291:427–434

pubmed: 14747499 doi: 10.1001/jama.291.4.427

Kruit MC, van Buchem MA, Launer LJ et al (2010) Migraine is associated with an increased risk of deep white matter lesions, subclinical posterior circulation infarcts and brain iron accumulation: the population-based MRI CAMERA study. Cephalalgia 30:129–136

pubmed: 19515125 pmcid: 3241741 doi: 10.1111/j.1468-2982.2009.01904.x

Iwasaki A, Suzuki K, Takekawa H et al (2017) The relationship between right-to-left shunt and brain white matter lesions in Japanese patients with migraine: a single center study. J Headache Pain 18:3

pubmed: 28063107 pmcid: 5218958 doi: 10.1186/s10194-016-0714-x

Zhao Q, Liu R, Zhou J et al (2021) Prevalence and grade of RLS in migraine: A prospective study of 251 migraineurs by synchronous test of c-TTE and c-TCD. Medicine (Baltimore) 100:e24175

pubmed: 33530208 doi: 10.1097/MD.0000000000024175

Meilán A, Larrosa D, Ramón C et al (2020) No association between migraine frequency, white matter lesions and silent brain infarctions: a study in a series of women with chronic migraine. Eur J Neurol 27:1689–1696

pubmed: 32343863 doi: 10.1111/ene.14284

Adelborg K, Szépligeti SK, Holland-Bill L et al (2018) Migraine and risk of cardiovascular diseases: Danish population based matched cohort study. BMJ 360:k96

pubmed: 29386181 doi: 10.1136/bmj.k96

Guey S, Mawet J, Hervé D et al (2016) Prevalence and characteristics of migraine in CADASIL. Cephalalgia 36:1038–1047

pubmed: 26646784 doi: 10.1177/0333102415620909

Rist PM, Winter AC, Buring JE et al (2018) Migraine and the risk of incident hypertension among women. Cephalalgia 38:1817–1824

pubmed: 29388437 doi: 10.1177/0333102418756865

Scher AI, Terwindt GM, Picavet HS et al (2005) Cardiovascular risk factors and migraine: the GEM population-based study. Neurology 64:614–620

pubmed: 15728281 doi: 10.1212/01.WNL.0000151857.43225.49

Øie LR, Kurth T, Gulati S et al (2020) Migraine and risk of stroke. J Neurol Neurosurg Psychiatry 91:593–604

pubmed: 32217787 doi: 10.1136/jnnp-2018-318254

Filippopulos FM, Schoeberl F, Becker HC et al (2019) Coronary artery calcification score in migraine patients. Sci Rep 9:14069

pubmed: 31575978 doi: 10.1038/s41598-019-50660-9

Wilson SL, Poulter NR (2006) The effect of non-steroidal anti-inflammatory drugs and other commonly used non-narcotic analgesics on blood pressure level in adults. J Hypertens 24:1457–1469

pubmed: 16877945 doi: 10.1097/01.hjh.0000239278.82196.a5

Petersen CL, Hougaard A, Gaist D et al (2024) Risk of Stroke and Myocardial Infarction Among Initiators of Triptans. JAMA Neurol 81:248–254

pubmed: 38315477 doi: 10.1001/jamaneurol.2023.5549

Mulder IA, Li M, de Vries T et al (2020) Anti-migraine calcitonin gene-related peptide receptor antagonists worsen cerebral ischemic outcome in mice. Ann Neurol 88:771–784

pubmed: 32583883 doi: 10.1002/ana.25831

Wang K, Fenton BT, Dao VX et al (2023) Trajectory of blood pressure after initiating anti-calcitonin gene-related peptide treatment of migraine: a target trial emulation from the veterans health administration. J Headache Pain 24:108

pubmed: 37582724 doi: 10.1186/s10194-023-01640-y

Battle DE (2013) Diagnostic and Statistical Manual of Mental Disorders (DSM). Codas 25:191–192

pubmed: 24413388

Kendler KS (1997) The genetic epidemiology of psychiatric disorders: a current perspective. Soc Psychiatry Psychiatr Epidemiol 32:5–11

pubmed: 9029981 doi: 10.1007/BF00800661

Merrill RM, Gibbons IS (2023) Comorbidity of sleep disorders, mental illness, and migraine or headaches. SN Compr Clin Med 5:283

doi: 10.1007/s42399-023-01622-w

Dresler T, Caratozzolo S, Guldolf K et al (2019) Understanding the nature of psychiatric comorbidity in migraine: a systematic review focused on interactions and treatment implications. J Headache Pain 20:51

pubmed: 31072313 pmcid: 6734261 doi: 10.1186/s10194-019-0988-x

Minen MT, Begasse De Dhaem O et al (2016) Migraine and its psychiatric comorbidities. J Neurol Neurosurg Psychiatry 87:741–749

pubmed: 26733600 doi: 10.1136/jnnp-2015-312233

Giri S, Tronvik EA, Hagen K (2022) The bidirectional temporal relationship between headache and affective disorders: longitudinal data from the HUNT studies. J Headache Pain 23:14

pubmed: 35062883 pmcid: 8903630 doi: 10.1186/s10194-022-01388-x

Burch RC, Buse DC, Lipton RB (2019) Migraine: epidemiology, burden, and comorbidity. Neurol Clin 37:631–649

pubmed: 31563224 doi: 10.1016/j.ncl.2019.06.001

Lampl C, Thomas H, Tassorelli C et al (2016) Headache, depression and anxiety: associations in the Eurolight project. J Headache Pain 17:59

pubmed: 27245683 pmcid: 4887397 doi: 10.1186/s10194-016-0649-2

Liu HY, Chou KH, Chen WT (2018) Migraine and the Hippocampus. Curr Pain Headache Rep 22:13

pubmed: 29404714 doi: 10.1007/s11916-018-0668-6

Burch R (2019) Antidepressants for preventive treatment of migraine. Current Treat Options Neurol 21:18

doi: 10.1007/s11940-019-0557-2

Jannini TB, Lorenzo GD, Bianciardi E et al (2022) Off-label Uses of Selective Serotonin Reuptake Inhibitors (SSRIs). Curr Neuropharmacol 20:693–712

pubmed: 33998993 pmcid: 9878961 doi: 10.2174/1570159X19666210517150418

Bromis K, Calem M, Reinders A et al (2018) Meta-analysis of 89 structural MRI studies in posttraumatic stress disorder and comparison with major depressive disorder. Am J Psychiatry 175:989–998

pubmed: 30021460 pmcid: 6169727 doi: 10.1176/appi.ajp.2018.17111199

Schoonman GG, Evers DJ, Terwindt GM et al (2006) (2006) The prevalence of premonitory symptoms in migraine: a questionnaire study in 461 patients. Cephalalgia 26:1209–1213

pubmed: 16961788 doi: 10.1111/j.1468-2982.2006.01195.x

Giffin NJ, Ruggiero L, Lipton RB et al (2003) Premonitory symptoms in migraine: an electronic diary study. Neurology 60:935–940

pubmed: 12654956 doi: 10.1212/01.WNL.0000052998.58526.A9

Gago-Veiga AB, Pagán J, Henares K et al (2018) To what extent are patients with migraine able to predict attacks? J Pain Res 11:2083–2094

pubmed: 30310310 doi: 10.2147/JPR.S175602

Xie YJ, Lin M, Wong YT et al (2022) Migraine attacks and relevant trigger factors in undergraduate nursing students in hong kong: a cross-sectional study. J Pain Res 15:701–713

pubmed: 35300404 doi: 10.2147/JPR.S337465

Lipton RB, Pavlovic JM, Haut SR et al (2014) Methodological issues in studying trigger factors and premonitory features of migraine. Headache 54:1661–1669

pubmed: 25339181 doi: 10.1111/head.12464

Schulte LH, Jürgens TP, May A (2015) Photo-, osmo- and phonophobia in the premonitory phase of migraine: mistaking symptoms for triggers? J Headache Pain 16:14

pubmed: 25904144 doi: 10.1186/s10194-015-0495-7

Wang X, Yin Z, Lian Y et al (2021) Premonitory symptoms in migraine from China: a multi-clinic study of 4821 patients. Cephalalgia 41:991–1003

pubmed: 33631964 doi: 10.1177/0333102421997850

Ferrari MD, Goadsby PJ, Burstein R et al (2022) Migraine Nat Rev Dis Primers 8:2

pubmed: 35027572 doi: 10.1038/s41572-021-00328-4

Puledda F, Silva EM, Suwanlaong K et al (2023) Migraine: from pathophysiology to treatment. J Neurol 270:3654–3666

pubmed: 37029836 doi: 10.1007/s00415-023-11706-1

Tu YH, Wang YF, Yuan H et al (2022) Most bothersome symptoms in patients with migraine: a hospital-based study in Taiwan. Headache 62:596–603

pubmed: 35467015 doi: 10.1111/head.14308

Munjal S, Singh P, Reed ML et al (2020) Most Bothersome symptom in persons with migraine: results from the Migraine in America Symptoms and Treatment (MAST) Study. Headache 60:416–429

pubmed: 31837007 doi: 10.1111/head.13708

Leao AAP (1944) Spreading depression of activity in the cerebral cortex. J Neurophysiol 7:359–390

doi: 10.1152/jn.1944.7.6.359

Gerstein MT, McGinley JS, Houts CR et al (2022) Non-ICHD-3 defning migraine symptoms by phase of the migraine cycle: results of the MiCOAS qualitative study. Headache 62(suppl 1):25

Bose P, Goadsby PJ (2016) The migraine postdrome. Curr Opin Neurol 29:299–301

pubmed: 26886356 doi: 10.1097/WCO.0000000000000310

Karsan N, Bose P, Goadsby PJ (2018) The migraine postdrome. Continuum (Minneap Minn) 24:996–1008

pubmed: 30074545

Recobe A (2021) Pathophysiology of migraine. Continuum (Minneap Minn) 27:586–596

Lipton RB, Dodick DW, Ailani J et al (2019) Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA 322:1887–1898

pubmed: 31742631 pmcid: 6865323 doi: 10.1001/jama.2019.16711

Villalón CM, VanDenBrink AM (2017) The role of 5-hydroxytryptamine in the pathophysiology of migraine and its relevance to the design of novel treatments. Mini Rev Med Chem 17:928–938

pubmed: 27465216 doi: 10.2174/1389557516666160728121050

Rubio-Beltrán E, Labastida-Ramírez A, Villalón CM et al (2018) Is selective 5-HT(1F) receptor agonism an entity apart from that of the triptans in antimigraine therapy? Pharmacol Ther 186:88–97

pubmed: 29352859 doi: 10.1016/j.pharmthera.2018.01.005

Doenicke A, Brand J, Perrin VL (1988) Possible benefit of GR43175, a novel 5-HT1-like receptor agonist, for the acute treatment of severe migraine. Lancet 1:1309–1311

pubmed: 2897560 doi: 10.1016/S0140-6736(88)92122-8

Rubio-Beltrán E, Labastida-Ramírez A, Haanes KA et al (2019) Characterization of binding, functional activity, and contractile responses of the selective 5-HT(1F) receptor agonist lasmiditan. Br J Pharmacol 176:4681–4695

pubmed: 31418454 pmcid: 6965684 doi: 10.1111/bph.14832

Loder E (2010) Triptan therapy in migraine. N Engl J Med 363:63–70

pubmed: 20592298 doi: 10.1056/NEJMct0910887

Benemei S, Cortese F, Labastida-Ramírez A et al (2017) Triptans and CGRP blockade - impact on the cranial vasculature. J Headache Pain 18:103

pubmed: 29019093 doi: 10.1186/s10194-017-0811-5

Cameron C, Kelly S, Hsieh SC et al (2015) Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache 55(Suppl 4):221–235

pubmed: 26178694 doi: 10.1111/head.12601

Ferrari MD, Roon KI, Lipton RB et al (2001) Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358:1668–1675

pubmed: 11728541 doi: 10.1016/S0140-6736(01)06711-3

VanderPluym JH, Halker Singh RB, Urtecho M et al (2021) Acute treatments for episodic migraine in adults: a systematic review and meta-analysis. JAMA 325:2357–2369

pubmed: 34128998 doi: 10.1001/jama.2021.7939

Nappi G, Sandrini G, Sances G (2003) Tolerability of the triptans: clinical implications. Drug Saf 26:93–107

pubmed: 12534326 doi: 10.2165/00002018-200326020-00003

Roberto G, Raschi E, Piccinni C et al (2015) Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies. Cephalalgia 35:118–131

pubmed: 25246519 doi: 10.1177/0333102414550416

Jamieson DG (2002) The safety of triptans in the treatment of patients with migraine. Am J Med 112:135–140

pubmed: 11835952 doi: 10.1016/S0002-9343(01)01064-6

Mitsikostas DD, Waeber C, Sanchez-Del-Rio M et al (2023) The 5-HT(1F) receptor as the target of ditans in migraine - from bench to bedside. Nat Rev Neurol 19:489–505

pubmed: 37438431 doi: 10.1038/s41582-023-00842-x

Mecklenburg J, Raffaelli B, Neeb L et al (2020) The potential of lasmiditan in migraine. Ther Adv Neurol Disord 13:1756286420967847

pubmed: 33403005 doi: 10.1177/1756286420967847

Raffaelli B, Israel H, Neeb L et al (2017) The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine. Expert Opin Pharmacother 18:1409–1415

pubmed: 28749698 doi: 10.1080/14656566.2017.1361406

Goadsby PJ, Duckworth JW (1987) Effect of stimulation of trigeminal ganglion on regional cerebral blood flow in cats. Am J Physiol 253:270–274

Goadsby PJ, Edvinsson L, Ekman R (1990) Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28:183–187

pubmed: 1699472 doi: 10.1002/ana.410280213

Levy D, Labastida-Ramirez A, MaassenVanDenBrink A (2019) Current understanding of meningeal and cerebral vascular function underlying migraine headache. Cephalalgia 39:1606–1622

pubmed: 29929378 doi: 10.1177/0333102418771350

Edvinsson L, Haanes KA, Warfvinge K (2018) CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol 14:338–350

pubmed: 29691490 doi: 10.1038/s41582-018-0003-1

Olesen J, Diener H-C, Husstedt IW et al (2004) Calcitonin gene–related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350:1104–1110

pubmed: 15014183 doi: 10.1056/NEJMoa030505

Hargreaves R, Olesen J (2019) Calcitonin gene-related peptide modulators - the history and renaissance of a new migraine drug class. Headache 59:951–970

pubmed: 31020659 doi: 10.1111/head.13510

Messina R, Huessler EM, Puledda F et al (2023) Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: a systematic review and network meta-analysis. Cephalalgia 43:3331024231152169

pubmed: 36786548 doi: 10.1177/03331024231152169

Labastida-Ramírez A, Caronna E, Gollion C et al (2023) Mode and site of action of therapies targeting CGRP signaling. J Headache Pain 24:125

pubmed: 37691118 doi: 10.1186/s10194-023-01644-8

Garelja ML, Walker CS, Hay DL (2022) CGRP receptor antagonists for migraine. Are they also AMY(1) receptor antagonists? Br J Pharmacol 179:454–459

pubmed: 34076887 doi: 10.1111/bph.15585

Edvinsson L, Grell AS, Warfvinge K (2020) Expression of the CGRP family of neuropeptides and their receptors in the trigeminal ganglion. J Mol Neurosci 70:930–944

pubmed: 32086679 doi: 10.1007/s12031-020-01493-z

Yang CP, Liang CS, Chang CM et al (2021) Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis. JAMA Netw Open 4:e2128544

pubmed: 34633423 doi: 10.1001/jamanetworkopen.2021.28544

Puledda F, Younis S, Huessler E-M et al (2023) Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: a systematic review and network meta-analysis of the literature. Cephalalgia 43:03331024231151419

doi: 10.1177/03331024231151419

Li D, Abreu J, Tepper SJ (2023) A brief review of gepants. Curr Pain Headache Rep 27:479–488

pubmed: 37531032 doi: 10.1007/s11916-023-01142-1

Maasumi K, Michael RL, Rapoport AM (2018) CGRP and migraine: the role of blocking calcitonin gene-related peptide ligand and receptor in the management of migraine. Drugs 78:913–928

pubmed: 29869205 doi: 10.1007/s40265-018-0923-5

Tajti J, Uddman R, Möller S et al (1999) Messenger molecules and receptor mRNA in the human trigeminal ganglion. J Auton Nerv Syst 76:176–183

pubmed: 10412842 doi: 10.1016/S0165-1838(99)00024-7

Ho TW, Edvinsson L, Goadsby PJ (2010) CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 6:573–582

pubmed: 20820195 doi: 10.1038/nrneurol.2010.127

Tfelt-Hansen P, Le H (2009) Calcitonin gene-related peptide in blood: is it increased in the external jugular vein during migraine and cluster headache? A review. J Headache Pain 10:137–143

pubmed: 19330286 doi: 10.1007/s10194-009-0112-8

Hansen JM, Hauge AW, Olesen J et al (2010) Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia 30:1179–1186

pubmed: 20855363 doi: 10.1177/0333102410368444

Ashina M (2020) Migraine. N Engl J Med 383:1866–1876

pubmed: 33211930 doi: 10.1056/NEJMra1915327

Lipton RB, Croop R, Stock EG et al (2019) Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med 381:142–149

pubmed: 31291516 doi: 10.1056/NEJMoa1811090

Croop R, Lipton RB, Kudrow D et al (2021) Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet 397:51–60

pubmed: 33338437 doi: 10.1016/S0140-6736(20)32544-7

Ailani J, Lipton RB, Goadsby PJ et al (2021) Atogepant for the preventive treatment of migraine. N Engl J Med 385:695–706

pubmed: 34407343 doi: 10.1056/NEJMoa2035908

Pozo-Rosich P, Ailani J, Ashina M et al (2023) Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 402:775–785

pubmed: 37516125 doi: 10.1016/S0140-6736(23)01049-8

Lipton RB, Croop R, Stock DA et al (2023) Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. Lancet Neurol 22:209–217

pubmed: 36804093 doi: 10.1016/S1474-4422(22)00517-8

Haghdoost F, Puledda F, Garcia-Azorin D et al (2023) Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia 43:3331024231159366

pubmed: 36855951 doi: 10.1177/03331024231159366

Schwedt TJ, Myers Oakes TM, Martinez JM et al (2024) Comparing the efficacy and safety of galcanezumab versus rimegepant for prevention of episodic migraine: results from a randomized, controlled clinical trial. Neurol Ther 13:85–105

pubmed: 37948006 doi: 10.1007/s40120-023-00562-w

Hong JB, Lange KS, Overeem LH et al (2023) A Scoping Review and Meta-Analysis of Anti-CGRP Monoclonal Antibodies: Predicting Response. Pharmaceuticals (Basel) 16:934

pubmed: 37513846 doi: 10.3390/ph16070934

Raffaelli B, Fitzek M, Overeem LH et al (2023) Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience. J Headache Pain 24:16

pubmed: 36843007 doi: 10.1186/s10194-023-01552-x

Barbanti P, Aurilia C, Egeo G et al (2023) Late response to anti-CGRP monoclonal antibodies in migraine: a multicenter prospective observational study. Neurology 101:482–488

pubmed: 37072224 doi: 10.1212/WNL.0000000000207292

Waliszewska-Prosół M, Vuralli D, Martelletti P (2023) What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants? J Headache Pain 24:163

pubmed: 38053061 doi: 10.1186/s10194-023-01698-8

Miyata A, Arimura A, Dahl RR et al (1989) Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 164:567–574

pubmed: 2803320 doi: 10.1016/0006-291X(89)91757-9

Miyata A, Jiang L, Dahl RD et al (1990) Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem Biophys Res Commun 170:643–648

pubmed: 2383262 doi: 10.1016/0006-291X(90)92140-U

Vaudry D, Falluel-Morel A, Bourgault S et al (2009) Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev 61:283–357

pubmed: 19805477 doi: 10.1124/pr.109.001370

Moller K, Zhang YZ, Håkanson R et al (1993) Pituitary adenylate cyclase activating peptide is a sensory neuropeptide: immunocytochemical and immunochemical evidence. Neuroscience 57:725–732

pubmed: 7508577 doi: 10.1016/0306-4522(93)90018-B

Mulder H, Uddman R, Moller K et al (1994) Pituitary adenylate cyclase activating polypeptide expression in sensory neurons. Neuroscience 63:307–312

pubmed: 7898655 doi: 10.1016/0306-4522(94)90025-6

Uddman R, Tajti J, Möller S et al (1999) Neuronal messengers and peptide receptors in the human sphenopalatine and otic ganglia. Brain Res 826:193–199

pubmed: 10224296 doi: 10.1016/S0006-8993(99)01260-3

Uddman R, Tajti J, Hou M et al (2002) Neuropeptide expression in the human trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2. Cephalalgia 22:112–116

pubmed: 11972578 doi: 10.1046/j.1468-2982.2002.00324.x

Rawlings SR (1994) PACAP, PACAP receptors, and intracellular signalling. Mol Cell Endocrinol 101:C5–C9

pubmed: 9397930 doi: 10.1016/0303-7207(94)90212-7

Knutsson M, Edvinsson L (2002) Distribution of mRNA for VIP and PACAP receptors in human cerebral arteries and cranial ganglia. NeuroReport 13:507–509

pubmed: 11930171 doi: 10.1097/00001756-200203250-00030

Chan KY, Baun M, De Vries R et al (2011) Pharmacological characterization of VIP and PACAP receptors in the human meningeal and coronary artery. Cephalalgia 31:181–189

pubmed: 20974589 doi: 10.1177/0333102410375624

Waschek JA, Baca SM, Akerman S (2018) PACAP and migraine headache: immunomodulation of neural circuits in autonomic ganglia and brain parenchyma. J Headache Pain 19:23

pubmed: 29536279 pmcid: 5849772 doi: 10.1186/s10194-018-0850-6

Wienholtz NKF, Christensen CE, Zhang DG et al (2021) Early treatment with sumatriptan prevents PACAP38-induced migraine: a randomised clinical trial. Cephalalgia 41:731–748

pubmed: 33567890 doi: 10.1177/0333102420975395

Tuka B, Helyes Z, Markovics A et al (2013) Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients. Cephalalgia. 33:1085–1095

pubmed: 23598374 doi: 10.1177/0333102413483931

Zagami AS, Edvinsson L, Goadsby PJ (2014) Pituitary adenylate cyclase activating polypeptide and migraine. Ann Clin Transl Neurol 1:1036–1040

pubmed: 25574477 pmcid: 4284128 doi: 10.1002/acn3.113

Guo S, Vollesen ALH, Hansen YB et al (2017) Part II: biochemical changes after pituitary adenylate cyclase-activating polypeptide-38 infusion in migraine patients. Cephalalgia 37:136–147

pubmed: 26994298 doi: 10.1177/0333102416639517

Sbei S, Moncrief T, Limjunyawong N et al (2023) PACAP activates MRGPRX2 on meningeal mast cells to drive migraine-like pain. Sci Rep 13:12302

pubmed: 37516794 pmcid: 10387048 doi: 10.1038/s41598-023-39571-y

Ashina M, Doležil D, Bonner JH et al (2021) A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention. Cephalalgia 41:33–44

pubmed: 33231489 doi: 10.1177/0333102420970889

Rasmussen NB, Deligianni C, Christensen CE et al (2023) The effect of Lu AG09222 on PACAP38- and VIP-induced vasodilation, heart rate increase, and headache in healthy subjects: an interventional, randomized, double-blind, parallel-group, placebo-controlled study. J Headache Pain 24:60

pubmed: 37231350 doi: 10.1186/s10194-023-01599-w

Grazzi L, Sansone M, Rizzoli P (2018) A short review of the Non-invasive transcutaneous pericranial electrical stimulation techniques and their application in headache. Curr Pain Head Rep 22:4

doi: 10.1007/s11916-018-0654-z

Tiwari V, Agrawal S (2022) Migraine and neuromodulation: a literature review. Cureus 14:e31223

pubmed: 36505141 pmcid: 9729750

Viganò A, Toscano M, Puledda F et al (2019) Treating chronic migraine with neuromodulation: the role of neurophysiological abnormalities and maladaptive plasticity. Front Pharmacol 10:32

pubmed: 30804782 pmcid: 6370938 doi: 10.3389/fphar.2019.00032

Hallett M (2007) Transcranial magnetic stimulation: a primer. Neuron 55:187–199

pubmed: 17640522 doi: 10.1016/j.neuron.2007.06.026

Andreou AP, Holland PR, Akerman S et al (2016) Transcranial magnetic stimulation and potential cortical and trigeminothalamic mechanisms in migraine. Brain 139:2002–2014

pubmed: 27246325 pmcid: 4939700 doi: 10.1093/brain/aww118

Cosentino G, Fierro B, Vigneri S et al (2014) Cyclical changes of cortical excitability and metaplasticity in migraine: evidence from a repetitive transcranial magnetic stimulation study. Pain 155:1070–1078

pubmed: 24631596 doi: 10.1016/j.pain.2014.02.024

Moisset X, Pereira B, Ciampi De Andrade D et al (2020) Neuromodulation techniques for acute and preventive migraine treatment: a systematic review and meta-analysis of randomized controlled trials. J Headache Pain 21:142

pubmed: 33302882 pmcid: 7726868 doi: 10.1186/s10194-020-01204-4

Shen M, Li C, Wei X et al (2023) Transcranial magnetic stimulation as a therapy for migraine: an overview of systematic reviews. J Pain Res 16:3133–3144

pubmed: 37724171 pmcid: 10505396 doi: 10.2147/JPR.S416993

Lipton RB, Dodick DW, Silberstein SD et al (2010) Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol 9:373–380

pubmed: 20206581 doi: 10.1016/S1474-4422(10)70054-5

De Couck M, Nijs J, Gidron Y (2014) You may need a nerve to treat pain: the neurobiological rationale for vagal nerve activation in pain management. Clin J Pain 30:1099–1105

pubmed: 24451632 doi: 10.1097/AJP.0000000000000071

Henssen DJHA, Derks B, van Doorn M et al (2019) Vagus nerve stimulation for primary headache disorders: an anatomical review to explain a clinical phenomenon. Cephalalgia 39:1180–1194

pubmed: 30786731 doi: 10.1177/0333102419833076

Grazzi L, Tassorelli C, de Tommaso M et al (2018) Practical and clinical utility of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: a post hoc analysis of the randomized, sham-controlled, double-blind PRESTO trial. J Headache Pain 19:98

pubmed: 30340460 doi: 10.1186/s10194-018-0928-1

Tassorelli C, Grazzi L, de Tommaso M et al (2018) Noninvasive vagus nerve stimulation as acute therapy for migraine: the randomized PRESTO study. Neurology 91:e364–e373

pubmed: 29907608 pmcid: 6070381 doi: 10.1212/WNL.0000000000005857

Grazzi L, Egeo G, Calhoun AH et al (2016) Non-invasive Vagus Nerve Stimulation (nVNS) as mini-prophylaxis for menstrual/menstrually related migraine: an open-label study. J Headache Pain 17:91

pubmed: 27699586 pmcid: 5047863 doi: 10.1186/s10194-016-0684-z

Song D, Li P, Wang Y et al (2023) Noninvasive vagus nerve stimulation for migraine: a systematic review and meta-analysis of randomized controlled trials. Front Neurol 14:1190062

pubmed: 37251233 pmcid: 10213755 doi: 10.3389/fneur.2023.1190062

Miller S, Sinclair AJ, Davies B et al (2016) Neurostimulation in the treatment of primary headaches. Pract Neurol 16:362–375

pubmed: 27152027 pmcid: 5036247 doi: 10.1136/practneurol-2015-001298

Ordas CM, Cuadrado ML, Pareja JA et al (2020) Transcutaneous supraorbital stimulation as a preventive treatment for chronic migraine: a prospective. Open-Label Study Pain Med 21:415–422

pubmed: 31131857

Reed KL (2013) Peripheral neuromodulation and headaches: clinical approach and considerations on underlying mechanisms. Curr Pain Head Rep 217:305

doi: 10.1007/s11916-012-0305-8

Magis D (2015) Neuromodulation in migraine: state of the art and perspectives. Expert Rev Med Devices 12:329–339

pubmed: 25633885 doi: 10.1586/17434440.2015.1005606

Subramonian A, Argaez C (2020) Non-invasive Nerve Stimulation Modalities for Migraine Pain: A Review of Clinical Effectiveness and Cost-effectiveness. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health

Thair H, Holloway AL, Newport R et al (2017) Transcranial Direct Current Stimulation (tDCS): a beginner’s guide for designe and implementation. Front Neurosci 11:641

pubmed: 29213226 pmcid: 5702643 doi: 10.3389/fnins.2017.00641

Vigneri S, Bonventre S, Inviati A et al (2014) Effects of transcranial direct current stimulation on esophageal motility in patients with gastroesophageal reflux disease. Clin Neurophysiol 125:1840–1846

pubmed: 24472614 doi: 10.1016/j.clinph.2013.12.110

Cai G, Xia Z, Charvet L et al (2021) A systematic review and meta-analysis on the efficacy of repeated transcranial direct current stimulation for migraine. J Pain Res 14:1171–1183

pubmed: 33953607 pmcid: 8090858 doi: 10.2147/JPR.S295704

Hong P, Liu Y, Wan Y et al (2022) Transcranial direct current stimulation for migraine: a systematic review and meta-analysis of randomized controlled trials. CNS Neurosci Ther 28:992–998

pubmed: 35437933 pmcid: 9160451 doi: 10.1111/cns.13843

Elyamany O, Leicht G, Herrmann CS et al (2021) Transcranial alternating current stimulation (tACS): From basic mechanisms towards first application in psychiatry. Eur Arch Psychiatry Clin Neurosci 271:135–156

pubmed: 33211157 doi: 10.1007/s00406-020-01209-9

Antal A, Bischoff R, Stephani C et al (2020) Low intensity, transcranial, alternating current stimulation reduces migraine attack burden in a home application set-up: a double-blinded, randomized feasibility study. Brain Sci 10:888

pubmed: 33233400 pmcid: 7700448 doi: 10.3390/brainsci10110888

Weeks RE (2013) Application of behavioral therapies in adult and adolescent patients with chronic migraine. Ital J Neurol Sci 34(Suppl 1):S11–S17

doi: 10.1007/s10072-013-1360-6

Faedda N, Cerutti R, Verdecchia P et al (2016) Behavioral management of headache in children and adolescents. J Headache Pain 17:80

pubmed: 27596923 pmcid: 5011470 doi: 10.1186/s10194-016-0671-4

Kabbouche MA, Gilman DK (2008) Management of migraine in adolescents. Neuropsychiatr Dis Treat 4:535–548

pubmed: 18830400 pmcid: 2526375 doi: 10.2147/NDT.S495

Harris P, Loveman E, Clegg A et al (2015) Systematic review of cognitive behavioural therapy for the management of headaches and migraines in adults. Br J Pain 2015:9213–9224

Kroner JW, Peugh J, Kashikar-Zuck SM et al (2017) Trajectory of improvement in children and adolescents with chronic migraine: results from the cognitive behavioral therapy and amitriptyline trial. J Pain 18:637–644

pubmed: 28108386 pmcid: 5457327 doi: 10.1016/j.jpain.2017.01.002

Powers SW, Kashikar-Zuck SM, Allen JR et al (2013) Cognitive behavioral therapy plus amitriptyline for chronic migraine in children and adolescents. JAMA 310:2622–2630

pubmed: 24368463 pmcid: 4865682 doi: 10.1001/jama.2013.282533

Lake AE 3rd (2001) Behavioral and nonpharmacologic treatments of headache. Med Clin North Am 85:1055–1075

pubmed: 11480258 doi: 10.1016/S0025-7125(05)70359-X

Carpino E, Segal S, Logan D et al (2014) The interplay of pain-related self-efficacy and fear on functional outcomes among youth with headache. J Pain 15:527–534

pubmed: 24462790 pmcid: 4012017 doi: 10.1016/j.jpain.2014.01.493

Short AL (2019) Enhancing migraine self-efficacy and reducing disability through a self-management program. J Am Assoc Nurse Pract 33:20–28

pubmed: 31738274 doi: 10.1097/JXX.0000000000000323

Mérelle SY, Sorbi MJ, Duivenvoorden HJ et al (2010) Qualities and health of lay trainers with migraine for behavioral attack prevention. Headache 50:613–625

pubmed: 20456149 doi: 10.1111/j.1526-4610.2008.01241.x

Allen LL, Haririfar M, Cohen J et al (2000) Quality of life and locus of control of migraineurs. Clin Excell Nurse Pract 4:41–49

pubmed: 11858296

Wells RE, O’Connell N, Pierce CR et al (2021) Effectiveness of mindfulness meditation vs headache education for adults with migraine: a randomized clinical trial. JAMA Intern Med 181:317–328

pubmed: 33315046 doi: 10.1001/jamainternmed.2020.7090

Grazzi L, Montisano DA, Rizzoli P et al (2023) A single-group study on the effect of onabotulinumtoxina in patients with chronic migraine associated with medication overuse headache: pain catastrophizing plays a role. Toxins (Basel) 15:86

pubmed: 36828401 doi: 10.3390/toxins15020086

Kleiboer A, Sorbi M, van Silfhout M et al (2014) Short-term effectiveness of an online behavioral training in migraine self-management: a randomized controlled trial. Behav Res Ther 61:61–69

pubmed: 25133856 doi: 10.1016/j.brat.2014.07.009

Raggi A, Grignani E, Leonardi M et al (2018) Behavioral approaches for primary headaches: recent advances. Headache 56:913–925

doi: 10.1111/head.13337

Grazzi L, Montisano DA, D’Amico D, et al (2024) Multimodal digital health treatments for Chronic Migraine associated with Medication Overuse Headache: a literature appraisal and results of a single-arm open trial (the BE-HOME program). Neurol Sci. https://doi.org/10.1007/s10072-024-07568-8 . Epub ahead of print, May 21, 2024

Licina E, Radojicic A, Jeremic M et al (2023) Non-pharmacological treatment of primary headaches-a focused review. Brain Sci 13:1432

pubmed: 37891800 doi: 10.3390/brainsci13101432

Meyer B, Keller A, Wöhlbier HG et al (2016) Progressive muscle relaxation reduces migraine frequency and normalizes amplitudes of contingent negative variation (CNV). J Headache Pain 9:213–224

Dobos D, Szabó E, Baksa D et al (2022) Regular practice of autogenic training reduces migraine frequency and is associated with brain activity changes in response to fearful visual stimuli. Front behav neurosci 15:780081

pubmed: 35126068 doi: 10.3389/fnbeh.2021.780081

Aemaz Ur Rehman M, Waseem R, Habiba U et al (2022) Efficacy of mindfulness-based intervention for the treatment of chronic headaches: a systematic review and meta-analysis. Ann Med Surg (Lond) 78:103862

pubmed: 35734718

Andrasik F, Grazzi L, D’Amico D et al (2016) Mindfulness and headache: a “new” old treatment, with new findings. Cephalalgia 36:1192–1205

pubmed: 27694139 doi: 10.1177/0333102416667023

Teasdale JD, Segal Z, Williams JM (1995) How does cognitive therapy prevent depressive relapse and why should attentional control (mindfulness) training help? Behav Res Ther 33:25–39

pubmed: 7872934 doi: 10.1016/0005-7967(94)E0011-7

Kabat-Zinn J (2013) Full catastrophe living: using the wisdom of your body and mind to face stress, pain, and illness. Bantam Books, New York

Sharma M, Rush SE (2014) Mindfulness-based stress reduction as a stress management intervention for healthy individuals: a systematic review. J Evid Based Complementary Altern Med 19:271–286

pubmed: 25053754 doi: 10.1177/2156587214543143

Zhang CQ, Leeming E, Smith P et al (2018) Acceptance and commitment therapy for health behavior change: a contextually-driven approach. Front Psychol 8:2350

pubmed: 29375451 doi: 10.3389/fpsyg.2017.02350

Bernstein CA, Connor JP, Vilsmark ES et al (2022) Acceptance and commitment therapy for episodic migraine: rationale and design of a pilot randomized controlled trial. Contemp Clin Trials 121:106907

pubmed: 36084899 doi: 10.1016/j.cct.2022.106907

Grazzi L, Andrasik F, Rizzoli P et al (2021) Acceptance and commitment therapy for high frequency episodic migraine without aura: findings from a randomized pilot investigation. Headache 61:895–905

pubmed: 34115399 doi: 10.1111/head.14139

Grazzi L, D’Amico D, Guastafierro E et al (2023) Efficacy of mindfulness added to treatment as usual in patients with chronic migraine and medication overuse headache: a phase-III single-blind randomized-controlled trial (the MIND-CM study). J Headache Pain 24:86

pubmed: 37452281 pmcid: 10347788 doi: 10.1186/s10194-023-01630-0

Fedeli D, Ciullo G, Demichelis G et al (2024) Longitudinal neurofunctional changes in medication overuse headache patients after mindfulness practice in a randomized controlled trial (the MIND-CM study). J Headache Pain 25:97

pubmed: 38858629 pmcid: 11165872 doi: 10.1186/s10194-024-01803-5

Faedda N, Natalucci G, Baglioni V et al (2019) Behavioral therapies in headache: focus on mindfulness and cognitive behavioral therapy in children and adolescents. Expert Rev Neurother 19:1219–1228

pubmed: 31422703 doi: 10.1080/14737175.2019.1654859

Gazerani P (2021) A bidirectional view of migraine and diet relationship. Neuropsychiatr Dis Treat 17:435–451

pubmed: 33603381 pmcid: 7884951 doi: 10.2147/NDT.S282565

Gazerani P (2023) Diet and migraine: what is proven? Curr Opin Neurol 36:615–621

pubmed: 37865855 doi: 10.1097/WCO.0000000000001204

Gazerani P (2020) Migraine and diet. Nutrients 12:1658

pubmed: 32503158 pmcid: 7352457 doi: 10.3390/nu12061658

Orr SL (2016) Diet and nutraceutical interventions for headache management: a review of the evidence. Cephalalgia 36(12):1112–1133. https://doi.org/10.1177/0333102415590239

doi: 10.1177/0333102415590239 pubmed: 26069242

Grazzi L, Rizzoli P (2021) Lessons from lockdown — behavioural interventions in migraine. Nat Rev Neurol 17:195–196

pubmed: 33637957 pmcid: 7909371 doi: 10.1038/s41582-021-00475-y

Grazzi L, Toppo C, D’Amico D et al (2021) Non-pharmacological approaches to headaches: non-invasive neuromodulation, nutraceuticals, and behavioral approaches. Int J Environ Res Public Health 18:1503

pubmed: 33562487 pmcid: 7914516 doi: 10.3390/ijerph18041503

Ariyanfar S, Razeghi Jahromi S, Togha M et al (2022) Review on headache related to dietary supplements. Curr Pain Headache Rep 26:193–218

pubmed: 35254637 doi: 10.1007/s11916-022-01019-9

D’Onofrio F, Raimo S, Spitaleri D et al (2017) Usefulness of nutraceuticals in migraine prophylaxis. Neurol Sci 38(Suppl 1):117–120

pubmed: 28527067 doi: 10.1007/s10072-017-2901-1

Kaur K, Hernandez V, Al Hajaj SW et al (2021) The efficacy of herbal supplements and nutraceuticals for prevention of migraine: can they help? Cureus 13:e14868

pubmed: 33972917

Papetti L, Moavero R, Ferilli MAN et al (2021) Truths and myths in pediatric migraine and nutrition. Nutrients 13:2714

pubmed: 34444875 doi: 10.3390/nu13082714

Di Lorenzo C, Coppola G, Bracaglia M et al (2019) A ketogenic diet normalizes interictal cortical but not subcortical responsivity in migraineurs. BMC Neurol 19:136

pubmed: 31228957 doi: 10.1186/s12883-019-1351-1

Di Lorenzo C, Pinto A, Ienca R et al (2019) A randomized double-blind, cross-over trial of very low-calorie diet in overweight migraine patients: a possible role for ketones? Nutrients 11:1742

pubmed: 31357685 doi: 10.3390/nu11081742

Rajapakse T, Pringsheim T (2016) Nutraceuticals in migraine: a summary of existing guidelines for use. Headache 56:808–816

pubmed: 26954394 doi: 10.1111/head.12789

Schoenen J, Jacquy J, Lenaerts M (1998) Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 50:466–470

pubmed: 9484373 doi: 10.1212/WNL.50.2.466

Sándor PS, Di Clemente L, Coppola G et al (2005) Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 64:713–715

pubmed: 15728298 doi: 10.1212/01.WNL.0000151975.03598.ED

Parohan M, Sarraf P, Javanbakht MH et al (2020) Effect of coenzyme Q10 supplementation on clinical features of migraine: a systematic review and dose-response meta-analysis of randomized controlled trials. Nutr Neurosci 23:868–875

pubmed: 30727862 doi: 10.1080/1028415X.2019.1572940

Teigen L, Boes CJ (2015) An evidence-based review of oral magnesium supplementation in the preventive treatment of migraine. Cephalalgia 35:912–922

pubmed: 25533715 doi: 10.1177/0333102414564891

Lipton RB, Göbel H, Einhäupl KM et al (2004) Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology 63:2240–2244

pubmed: 15623680 doi: 10.1212/01.WNL.0000147290.68260.11

Diener HC, Freitag FG, Danesch U (2018) Safety profile of a special butterbur extract from Petasites hybridus in migraine prevention with emphasis on the liver. Cephalalgia Reports 1:2515816318759304

doi: 10.1177/2515816318759304

Pittler MH, Ernst E (2004) Feverfew for preventing migraine. Cochrane Database Syst Rev. 2004:Cd002286

Pradalier A, Bakouche P, Baudesson G et al (2001) Failure of omega-3 polyunsaturated fatty acids in prevention of migraine: a double-blind study versus placebo. Cephalalgia 21:818–822

pubmed: 11737007 doi: 10.1046/j.1468-2982.2001.218240.x

Ramsden CE, Zamora D, Faurot KR et al (2021) Dietary alteration of n-3 and n-6 fatty acids for headache reduction in adults with migraine: randomized controlled trial. BMJ 374:n1448

pubmed: 34526307 doi: 10.1136/bmj.n1448

Wang HF, Liu WC, Zailani H et al (2024) A 12-week randomized double-blind clinical trial of eicosapentaenoic acid intervention in episodic migraine. Brain Behav Immun 118:459–467

pubmed: 38499208 doi: 10.1016/j.bbi.2024.03.019

Chirchiglia D, Cione E, Caroleo MC et al (2018) Effects of add-on ultramicronized N-palmitol ethanol amide in patients suffering of migraine with aura: a pilot study. Front Neurol 9:674

pubmed: 30177906 doi: 10.3389/fneur.2018.00674

Papetti L, Sforza G, Tullo G et al (2020) Tolerability of palmitoylethanolamide in a pediatric population suffering from migraine: a pilot study. Pain Res Manag 2020:3938640

pubmed: 32377286 doi: 10.1155/2020/3938640

Usai S, Grazzi L, Bussone G (2011) Gingkolide B as migraine preventive treatment in young age: results at 1-year follow-up. Neurol Sci 32(Suppl 1):S197–S199

pubmed: 21533745 doi: 10.1007/s10072-011-0522-7

Holdridge A, Donnelly M, Kuruvilla DE (2022) Integrative, interventional, and non-invasive approaches for the treatment for migraine during pregnancy. Curr Pain Headache Rep 26:323–330

pubmed: 35362816 doi: 10.1007/s11916-022-01028-8

Makrides M, Crosby DD, Bain E et al (2014) Magnesium supplementation in pregnancy. Cochrane Database Syst Rev. 2014:Cd000937

pubmed: 24696187

Institute of Medicine Standing Committee on the Scientific Evaluation of Dietary Reference I, its Panel on Folate OBV, Choline (1998) Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B(6), Folate, Vitamin B(12), Pantothenic Acid, Biotin, and Choline. Washington (DC): National Academies Press. Available at: https://www.ncbi.nlm.nih.gov/books/NBK114310/ . Accessed 18 July 2024

Teran E, Hernandez I, Nieto B et al (2009) Coenzyme Q10 supplementation during pregnancy reduces the risk of pre-eclampsia. Int J Gynaecol Obstet 105:43–45

pubmed: 19154996 doi: 10.1016/j.ijgo.2008.11.033

Guilbot A, Bangratz M, Ait Abdellah S et al (2017) A combination of coenzyme Q10, feverfew and magnesium for migraine prophylaxis: a prospective observational study. BMC Complement Altern Med 17:433

pubmed: 28854909 doi: 10.1186/s12906-017-1933-7

Negro A, Delaruelle Z, Ivanova TA et al (2017) Headache and pregnancy: a systematic review. J Headache Pain 18:106

pubmed: 29052046 doi: 10.1186/s10194-017-0816-0

Papetti L, Ursitti F, Moavero R et al (2019) Prophylactic treatment of pediatric migraine: is there anything new in the last decade? Front Neurol 10:771

pubmed: 31379721 doi: 10.3389/fneur.2019.00771

Wells RE, Bertisch SM, Buettner C et al (2011) Complementary and alternative medicine use among adults with migraines/severe headaches. Headache 51:1087–1097

pubmed: 21649654 doi: 10.1111/j.1526-4610.2011.01917.x

Onan D, Ekizoğlu E, Arıkan H et al (2023) The efficacy of physical therapy and rehabilitation approaches in chronic migraine: a systematic review and meta-analysis. J Integr Neurosci 22:126

pubmed: 37735140 doi: 10.31083/j.jin2205126

Onan D, Arıkan H, Martelletti P (2023) The effect of onabotulinumtoxina on headache intensity and number of monthly headache days in individuals with chronic migraine with different levels of neck disability. Toxins (Basel) 15:685

pubmed: 38133189 doi: 10.3390/toxins15120685

Woldeamanuel YW, Oliveira ABD (2022) What is the efficacy of aerobic exercise versus strength training in the treatment of migraine? A systematic review and network meta-analysis of clinical trials. J Headache Pain 23:134

pubmed: 36229774 pmcid: 9563744 doi: 10.1186/s10194-022-01503-y

Sari Aslani P, Hassanpour M, Razi O et al (2022) Resistance training reduces pain indices and improves quality of life and body strength in women with migraine disorders. Sport Sci Health 18:433–443

doi: 10.1007/s11332-021-00822-y

Benatto MT, Florencio LL, Bragatto MM et al (2022) Neck-specific strengthening exercise compared with placebo sham ultrasound in patients with migraine: a randomized controlled trial. BMC Neurol 22:126

pubmed: 35366822 pmcid: 8976325 doi: 10.1186/s12883-022-02650-0

Sun L, Li G, Liu F et al (2022) Resistance exercise relieves symptoms of vestibular migraine patients with MRI diagnosis: a randomized parallel-controlled single-blind clinical trial. Rev Neurol (Paris) 178:370–376

pubmed: 34598780 doi: 10.1016/j.neurol.2021.06.008

La Touche R, Fierro-Marrero J, Sánchez-Ruíz I et al (2023) Prescription of therapeutic exercise in migraine, an evidence-based clinical practice guideline. J Headache Pain 24:68

pubmed: 37286937 doi: 10.1186/s10194-023-01571-8

Rainero I, Rubino E, Gallone S et al (2011) Evidence for an association between migraine and the hypocretin receptor 1 gene. J Headache Pain 12:193–199

pubmed: 21344296 doi: 10.1007/s10194-011-0314-8

Watanabe H, Kuwabara T, Ohkubo M et al (1996) Elevation of cerebral lactate detected by localized 1H-magnetic resonance spectroscopy in migraine during the interictal period. Neurology 47:1093–1095

pubmed: 8857754 doi: 10.1212/WNL.47.4.1093

Jonhagen S, Ackermann P, Saartok T et al (2006) Calcitonin gene related peptide and neuropeptide Y in skeletal muscle after eccentric exercise: a microdialysis study. Br J Sports Med 40:264–267

pubmed: 16505086 doi: 10.1136/bjsm.2005.022731

Dittrich SM, Günther V, Franz G et al (2008) Aerobic exercise with relaxation: influence on pain and psychological well-being in female migraine patients. Clin J Sport Med 18:363–365

pubmed: 18614890 doi: 10.1097/JSM.0b013e31817efac9

Dinoff A, Herrmann N, Swardfager W et al (2016) The effect of exercise training on resting concentrations of peripheral Brain-Derived Neurotrophic Factor (BDNF): a meta-analysis. PLoS One 11:e0163037

pubmed: 27658238 doi: 10.1371/journal.pone.0163037

Amin FM, Aristeidou S, Baraldi C et al (2018) The association between migraine and physical exercise. J Headache Pain 19:83

pubmed: 30203180 doi: 10.1186/s10194-018-0902-y

Sparling PB, Giuffrida A, Piomelli D et al (2003) Exercise activates the endocannabinoid system. NeuroReport 14:2209–2211

pubmed: 14625449 doi: 10.1097/00001756-200312020-00015

Demarquay G, Mawet J, Guégan-Massardier E et al (2021) Revised guidelines of the French headache society for the diagnosis and management of migraine in adults. Part 3: Non-pharmacological treatment. Rev Neurol (Paris) 177:753–759

pubmed: 34340809 doi: 10.1016/j.neurol.2021.07.009

Schytz HW, Amin FM, Jensen RH et al (2021) Reference programme: diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 3rd edition, 2020. J Headache Pain. 22:22

pubmed: 33832438 doi: 10.1186/s10194-021-01228-4

American Headache Society (2019) The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache 59:1–18

doi: 10.1111/head.13456

Reina-Varona Á, Madroñero-Miguel B, Gaul C et al (2023) Therapeutic exercise parameters, considerations, and recommendations for migraine treatment: an international delphi study. Phys Ther. 103:pzad080

pubmed: 37410390 doi: 10.1093/ptj/pzad080

Moore CS, Sibbritt DW, Adams J (2017) A critical review of manual therapy use for headache disorders: prevalence, profiles, motivations, communication and self-reported effectiveness. BMC Neurol 17:61

pubmed: 28340566 pmcid: 5364599 doi: 10.1186/s12883-017-0835-0

Rist PM, Hernandez A, Bernstein C et al (2019) The impact of spinal manipulation on migraine pain and disability: a systematic review and meta-analysis. Headache 59:532–542

pubmed: 30973196 pmcid: 6461372 doi: 10.1111/head.13501

Chaibi A, Tuchin PJ, Russell MB (2011) Manual therapies for migraine: a systematic review. J Headache Pain 12:127–133

pubmed: 21298314 pmcid: 3072494 doi: 10.1007/s10194-011-0296-6

Muñoz-Gómez E, Inglés M, Serra-Añó P et al (2021) Effectiveness of a manual therapy protocol based on articulatory techniques in migraine patients. A randomized controlled trial. Musculoskelet Sci Pract. 54:102386

pubmed: 33989990 doi: 10.1016/j.msksp.2021.102386

Bialosky JE, Bishop MD, Price DD et al (2009) The mechanisms of manual therapy in the treatment of musculoskeletal pain: a comprehensive model. Man Ther 14:531–538

pubmed: 19027342 doi: 10.1016/j.math.2008.09.001

Muñoz-Gómez E, Serra-Añó P, Mollà-Casanova S et al (2022) Potential add-on effects of manual therapy techniques in migraine patients: a randomised controlled trial. J Clin Med 11:4686

pubmed: 36012924 pmcid: 9410040 doi: 10.3390/jcm11164686

Di Antonio S, Arendt-Nielsen L, Castaldo M (2023) Cervical musculoskeletal impairments and pain sensitivity in migraine patients. Musculoskelet Sci Pract 66:102817

pubmed: 37451884 doi: 10.1016/j.msksp.2023.102817

Di Antonio S, Arendt-Nielsen L, Ponzano M et al (2023) Migraine patients with and without neck pain: differences in clinical characteristics, sensitization, musculoskeletal impairments, and psychological burden. Musculoskelet Sci Pract 66:102800

pubmed: 37344290 doi: 10.1016/j.msksp.2023.102800

Szikszay TM, Hoenick S, von Korn K et al (2019) Which examination tests detect differences in cervical musculoskeletal impairments in people with migraine? A systematic review and meta-analysis. Phys Ther 99:549–569

pubmed: 30690564 doi: 10.1093/ptj/pzz007

Di Antonio S, Arendt-Nielsen L, Ponzano M et al (2022) Cervical musculoskeletal impairments in the 4 phases of the migraine cycle in episodic migraine patients. Cephalalgia 42:827–845

pubmed: 35332826 doi: 10.1177/03331024221082506

Tedeschi R, Pillastrini P, Pierangeli G et al (2024) Is physiotherapy in migraines known to sufferers? A cross-sectional study. Neurol Sci 45:1669–1674

pubmed: 37966625 doi: 10.1007/s10072-023-07195-9

Louw A, Diener I, Butler DS et al (2011) The effect of neuroscience education on pain, disability, anxiety, and stress in chronic musculoskeletal pain. Arch Phys Med Rehabil 92:2041–2056

pubmed: 22133255 doi: 10.1016/j.apmr.2011.07.198

Kindelan-Calvo P, Gil-Martínez A, Paris-Alemany A et al (2014) Effectiveness of therapeutic patient education for adults with migraine. A systematic review and meta-analysis of randomized controlled trials. Pain Med 15:1619–1636

pubmed: 25159212 doi: 10.1111/pme.12505

Meise R, Carvalho GF, Thiel C et al (2023) Additional effects of pain neuroscience education combined with physiotherapy on the headache frequency of adult patients with migraine: a randomized controlled trial. Cephalalgia 43:3331024221144781

pubmed: 36739510 doi: 10.1177/03331024221144781

Fernández-de-Las-Peñas C, Navarro-Santana MJ, Curiel-Montero F et al (2022) Localized and widespread pressure pain hypersensitivity in patients with episodic or chronic migraine: a systematic review and meta-analysis. Cephalalgia 42:966–980

pubmed: 35332797 doi: 10.1177/03331024221084217

Di Antonio S, Arendt-Nielsen L, Ponzano M et al (2024) Profiling migraine patients according to clinical and psychophysical characteristics: clinical validity of distinct migraine clusters. Neurol Sci 45:1185–1200

pubmed: 37833507 doi: 10.1007/s10072-023-07118-8

Edwards RR, Dworkin RH, Turk DC et al (2016) Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations. Pain 157:1851–1871

pubmed: 27152687 pmcid: 5965275 doi: 10.1097/j.pain.0000000000000602

World Health Organization (2024) “What is Pharmacovigilance?”. Available at: https://www.who.int/teams/regulation-prequalification/regulation-and-safety/pharmacovigilance#:~:text=Pharmacovigilance%20is%20the%20science%20and,other%20medicine%2Fvaccine%20related%20problem . Accessed 18 July 2024

Gérard AO, Merino D, Van Obberghen EK et al (2022) Calcitonin gene-related peptide-targeting drugs and Raynaud’s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database. J Headache Pain 23:53

pubmed: 35505285 pmcid: 9066820 doi: 10.1186/s10194-022-01424-w

Woods RH (2022) Alopecia signals associated with calcitonin gene-related peptide inhibitors in the treatment or prophylaxis of migraine: a pharmacovigilance study. Pharmacotherapy 42:758–767

pubmed: 35975575 doi: 10.1002/phar.2725

Roberto G, Piccinni C, D’Alessandro R et al (2014) Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database. Cephalalgia 34:5–13

pubmed: 23921799 doi: 10.1177/0333102413499649

Beau-Salinas F, Jonville-Béra AP, Cissoko H et al (2010) Drug dependence associated with triptans and ergot derivatives: a case/non-case study. Eur J Clin Pharmacol 66:413–417

pubmed: 20024536 doi: 10.1007/s00228-009-0769-6

Millson D, Frischer M, Croft P et al (2000) Are triptans with enhanced lipophilicity used for the acute treatment of migraine associated with an increased consulting rate for depressive illness? Cephalalgia 20:732–737

pubmed: 11167903 doi: 10.1111/j.1468-2982.2000.00111.x

Conijn M, Maas V, van Tuyl M, et al (2024) Breastfeeding-related adverse drug reactions of triptans: a descriptive analysis using four pharmacovigilance databases. Breastfeed Med. https://doi.org/10.1089/bfm.2024.0022 . Epub ahead of print, Apr 2, 2024

Merino D, Gérard AO, Van Obberghen EK et al (2023) The neuropsychiatric safety profile of lasmiditan: a comparative disproportionality analysis with triptans. Neurotherapeutics 20:1305–1315

pubmed: 37436579 pmcid: 10480366 doi: 10.1007/s13311-023-01404-1

Wan X, Zhang S, Jiang C, et al (2024) Safety profile of lasmiditan: a retrospective post-marketing pharmacovigilance study based on the real-world data of FAERS database. Expert Opin Drug Saf. https://doi.org/10.1080/14740338.2024.2371382 2024 Epub ahead of print, Jun 20, 2024

Battini V, Carnovale C, Clementi E et al (2023) Ubrogepant and rimegepant: signal detection using spontaneous reports of adverse events from the Food and Drug Administration Adverse Event Reporting System. Expert Opin Drug Saf 22:1105–1112

pubmed: 37293948 doi: 10.1080/14740338.2023.2223958

Cao B, Gu S, Shen Z et al (2024) Evaluating Ubrogepant-related adverse events using the FDA adverse event reporting system. Expert Opin Drug Saf 23:297–303

pubmed: 37608560 doi: 10.1080/14740338.2023.2251390

Blumenfeld AM, Kaur G, Mahajan A et al (2023) Effectiveness and safety of chronic migraine preventive treatments: a systematic literature review. Pain Ther 12:251–274

pubmed: 36417165 doi: 10.1007/s40122-022-00452-3

Holzer P, Holzer-Petsche U (2021) Constipation caused by anti-calcitonin gene-related peptide migraine therapeutics explained by antagonism of calcitonin gene-related peptide’s motor-stimulating and prosecretory function in the intestine. Front Physiol 12:820006

pubmed: 35087426 doi: 10.3389/fphys.2021.820006

Ihara K, Takizawa T, Watanabe N et al (2024) Potential benefits and possible risks of CGRP-targeted multitherapy in migraine. Expert Opin Drug Metab Toxicol 20:1–4

pubmed: 38323326 doi: 10.1080/17425255.2024.2316131

Silberstein SD, Reshef S, Cohen JM et al (2023) Adverse events reported with therapies targeting the CGRP pathway during the first 6 months post-launch: a retrospective analysis using the FDA adverse events reporting system. Adv Ther 40:445–459

pubmed: 36350532 doi: 10.1007/s12325-022-02346-4

Robblee J, Harvey LK (2022) Cardiovascular disease and migraine: are the new treatments safe? Curr Pain Headache Rep 26:647–655

pubmed: 35751798 doi: 10.1007/s11916-022-01064-4

Chhabra N, Mead-Harvey C, Dodoo CA et al (2024) Blood pressure elevation in erenumab-treated patients with migraine: a retrospective real-world experience. Headache 64:233–242

pubmed: 38411625 doi: 10.1111/head.14679

Perino J, Corand V, Laurent E et al (2022) Myocardial infarction associated with erenumab: a case report. Pharmacotherapy 42:585–589

pubmed: 35620946 pmcid: 9541222 doi: 10.1002/phar.2706

Noseda R, Bedussi F, Gobbi C et al (2021) Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: analysis of the WHO pharmacovigilance database. Cephalalgia 41:789–798

pubmed: 33435709 doi: 10.1177/0333102420983292

Noseda R, Bedussi F, Gobbi C et al (2023) Safety profile of monoclonal antibodies targeting the calcitonin gene-related peptide system in pregnancy: updated analysis in VigiBase®. Cephalalgia 43:03331024231158083

doi: 10.1177/03331024231158083

Shafei L, Mekki L, Maklad E et al (2023) Factors that influence patient and public adverse drug reaction reporting: a systematic review using the theoretical domains framework. Int J Clin Pharm 45:801–813

pubmed: 37247158 pmcid: 10366238 doi: 10.1007/s11096-023-01591-z

Hartnell NR, Wilson JP (2004) Replication of the weber effect using postmarketing adverse event reports voluntarily submitted to the United States food and drug administration. Pharmacotherapy 24:743–749

pubmed: 15222664 doi: 10.1592/phco.24.8.743.36068

Negro A, Martelletti P (2011) Chronic migraine plus medication overuse headache: two entities or not? J Headache Pain 12:593–601

pubmed: 21938457 pmcid: 3208042 doi: 10.1007/s10194-011-0388-3

Committee HC, Olesen J, Bousser MG et al (2006) New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 26:742–746

doi: 10.1111/j.1468-2982.2006.01172.x

Welch K, Goadsby P (2002) Chronic daily headache: nosology and pathophysiology. Curr Opin Neurol 15:287–295

pubmed: 12045727 doi: 10.1097/00019052-200206000-00011

Torres-Ferrús M, Ursitti F, Alpuente A et al (2020) From transformation to chronification of migraine: pathophysiological and clinical aspects. J Headache Pain 21:42

pubmed: 32349653 pmcid: 7189559 doi: 10.1186/s10194-020-01111-8

Weatherall MW (2015) The diagnosis and treatment of chronic migraine. Ther Adv Chronic Dis 6:115–123

pubmed: 25954496 pmcid: 4416971 doi: 10.1177/2040622315579627

Gosalia H, Moreno-Ajona D, Goadsby PJ (2024) Medication-overuse headache: a narrative review. J Headache Pain 25:89

pubmed: 38816828 pmcid: 11140994 doi: 10.1186/s10194-024-01755-w

Ferrari A, Baraldi C, Sternieri E (2015) Medication overuse and chronic migraine: a critical review according to clinical pharmacology. Expert Opin Drug Metab Toxicol 11:1127–1144

pubmed: 26027878 doi: 10.1517/17425255.2015.1043265

Tana C, Raffaelli B, Souza MNP et al (2024) Health equity, care access and quality in headache - part 1. J Headache Pain 25:12

pubmed: 38281917 pmcid: 10823691 doi: 10.1186/s10194-024-01712-7

Raffaelli B, Rubio-Beltrán E, Cho SJ et al (2023) Health equity, care access and quality in headache - part 2. J Headache Pain 24:167

pubmed: 38087219 pmcid: 10717448 doi: 10.1186/s10194-023-01699-7

Shao SC, Hentz J, Shank P et al (2024) Functional impairment of chronic migraine with medication overuse: Secondary analysis from the Medication Overuse Treatment Strategy (MOTS) trial. Headache 64:632–642

pubmed: 38780360 doi: 10.1111/head.14732

Diener HC, Kropp P, Dresler T et al (2022) Management of medication overuse (MO) and medication overuse headache (MOH) S1 guideline. Neurol Res Pract 4:37

pubmed: 36031642 pmcid: 9422154 doi: 10.1186/s42466-022-00200-0

Tana C, Cipollone F, Giamberardino MA (2023) New therapeutic options for migraine. Curr Pharm Des 29:1964–1966

pubmed: 37605392 doi: 10.2174/1381612829666230821092238

Tana C, Cipollone F, Giamberardino MA et al (2023) New drugs targeting calcitonin gene-related peptide for the management of migraines. Expert Opin Emerg Drugs 28:233–240

pubmed: 37996401 doi: 10.1080/14728214.2023.2288334

Lipton RB, Silberstein SD (2015) Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache 55(Suppl 2):103–122

pubmed: 25662743 doi: 10.1111/head.12505_2

GBD (2021) Diseases and Injuries Collaborators (2024) Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 403:2133–2161

May A, Schulte LH (2016) Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol 12:455–464

pubmed: 27389092 doi: 10.1038/nrneurol.2016.93

Buse DC, Greisman JD, Baigi K et al (2019) Migraine progression: a systematic review. Headache 59:306–338

pubmed: 30589090 doi: 10.1111/head.13459

Tana C, Bentivegna E, Cho SJ, Harriott AM et al (2022) Long COVID headache. J Headache Pain 23:93

pubmed: 35915417 doi: 10.1186/s10194-022-01450-8

Tana C, Giamberardino MA, Martelletti P (2023) Long COVID and especially headache syndromes. Curr Opin Neurol 36:168–174

pubmed: 37078648

Waliszewska-Prosół M, Budrewicz S (2021) The unusual course of a migraine attack during COVID-19 infection - Case studies of three patients. J Infect Public Health 14:903–905

pubmed: 34119843 doi: 10.1016/j.jiph.2021.04.013

Moïsi L, Mino JC, Guidet B et al (2024) Frailty assessment in critically ill older adults: a narrative review. Ann Intensive Care 14:93

pubmed: 38888743 doi: 10.1186/s13613-024-01315-0

Tana C, Moffa L, Falasca K et al (2023) Approach to COVID-19 in older adults and indications for improving the outcomes. Ann Med 55:2265298

pubmed: 37839411 doi: 10.1080/07853890.2023.2265298

Tana C (2024) Editorial: Frailty in older patients during the COVID-19 era. Front Med (Lausanne) 10:1348468

pubmed: 38249977 doi: 10.3389/fmed.2023.1348468

Ornello R, Andreou AP, De Matteis E et al (2024) Resistant and refractory migraine: clinical presentation, pathophysiology, and management. EBioMedicine 99:104943

pubmed: 38142636 doi: 10.1016/j.ebiom.2023.104943

Sacco S, Braschinsky M, Ducros A et al (2020) European headache federation consensus on the definition of resistant and refractory migraine: developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain. 21:76

pubmed: 32546227 pmcid: 7296705 doi: 10.1186/s10194-020-01130-5

Waliszewska-Prosół M, Nowakowska-Kotas M, Chojdak-Łukasiewicz J et al (2021) Migraine and sleep-an unexplained association? Int J Mol Sci 22:5539

pubmed: 34073933 doi: 10.3390/ijms22115539

Caronna E, Gallardo VJ, Egeo G, et al (2024) Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world. J Neurol Neurosurg Psychiatry. https://doi.org/10.1136/jnnp-2023-333295 . Epub ahead of print, May 22, 2024

Steiner TJ, Stovner LJ, Jensen R et al (2020) Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J Headache Pain 21:137

pubmed: 33267788 pmcid: 7708887 doi: 10.1186/s10194-020-01208-0

Stewart WF, Lipton RB, Dowson AJ et al (2001) Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology 56(6 Suppl 1):S20–S28

pubmed: 11294956

McKenna SP, Doward LC, Davey KM (1998) The Development and Psychometric Properties of the MSQOL: A Migraine-Specific Quality-of-Life Instrument. Clin Drug Investig 15:413–423

pubmed: 18370497 doi: 10.2165/00044011-199815050-00006

Kosinski M, Bayliss MS, Bjorner JB et al (2003) A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 12:963–974

pubmed: 14651415 doi: 10.1023/A:1026119331193

Raggi A, Grazzi L, Grignani E et al (2018) The use of MIDAS in patients with chronic migraine and medication-overuse headache: should we trust it? Neurol Sci 39(Suppl 1):125–127

pubmed: 29904852 doi: 10.1007/s10072-018-3373-7

Leonardi M, Raggi A, Bussone G et al (2010) Health-related quality of life, disability and severity of disease in patients with migraine attending to a specialty headache center. Headache 50:1576–1586

pubmed: 21029083 doi: 10.1111/j.1526-4610.2010.01770.x

Seo J-G, Park S-P (2015) Validation of the Patient Health Questionnaire-9 (PHQ-9) and PHQ-2 in patients with migraine. J Headache Pain 16:65

pubmed: 26174509 pmcid: 4501946 doi: 10.1186/s10194-015-0552-2

D’Amico D, Tepper SJ, Guastafierro E et al (2021) Mapping assessments instruments for headache disorders against the ICF biopsychosocial model of health and disability. Int J Environ Res Public Health 18:246

doi: 10.3390/ijerph18010246

Leonardi M, Steiner TJ, Scher AT et al (2005) The global burden of migraine: measuring disability in headache disorders with WHO’s Classification of Functioning, Disability and Health (ICF). J Headache Pain 6:429–440

pubmed: 16388337 pmcid: 3452308 doi: 10.1007/s10194-005-0252-4

Raggi A, Giovannetti AM, Quintas R et al (2012) A systematic review of the psychosocial difficulties relevant to patients with migraine. J Headache Pain 13:595–606

pubmed: 23001069 pmcid: 3484254 doi: 10.1007/s10194-012-0482-1

Duan S, Ren Z, Xia H et al (2023) Associations between anxiety, depression with migraine, and migraine-related burdens. Front Neurol 14:1090878

pubmed: 37181566 doi: 10.3389/fneur.2023.1090878

Peres MFP, Mercante JPP, Tobo PR et al (2017) Anxiety and depression symptoms and migraine: a symptom-based approach research. J Headache Pain 18:37

pubmed: 28324317 doi: 10.1186/s10194-017-0742-1

Rammohan K, Mundayadan SM, Das S et al (2019) Migraine and mood disorders: prevalence, clinical correlations and disability. J Neurosci Rural Pract 10:28–33

pubmed: 30765967 doi: 10.4103/jnrp.jnrp_146_18

Della Vecchia A, De Luca C, Becattini L et al (2024) Beyond pain relief: unveiling the multifaceted impact of Anti-CGRP/R mAbs on comorbid symptoms in resistant migraine patients. Biomedicines 12:677

pubmed: 38540290 doi: 10.3390/biomedicines12030677

Castro Zamparella T, Carpinella M, Peres M et al (2024) Specific cognitive and psychological alterations are more strongly linked to increased migraine disability than chronic migraine diagnosis. J Headache Pain 25:37

pubmed: 38486142 doi: 10.1186/s10194-024-01734-1

Torres-Ferrús M, Gallardo VJ, Alpuente A et al (2024) Improvement of migraine depressive symptoms is not related to headache frequency: exploring the impact of anti-CGRP therapies. Cephalalgia 44:03331024231222923

doi: 10.1177/03331024231222923

Stubberud A, Buse DC, Kristoffersen ES et al (2021) Is there a causal relationship between stress and migraine? Current evidence and implications for management. J Headache Pain 22:155

pubmed: 34930118 doi: 10.1186/s10194-021-01369-6

Perozzo P, Savi L, Castelli L et al (2005) Anger and emotional distress in patients with migraine and tension-type headache. J Headache Pain 6:392–399

pubmed: 16362712 doi: 10.1007/s10194-005-0240-8

Seo JG, Park SP (2018) Significance of fatigue in patients with migraine. J Clin Neurosci 50:69–73

pubmed: 29396068 doi: 10.1016/j.jocn.2018.01.032

Garcia-Monco JC, Foncea N, Bilbao A et al (2007) Impact of preventive therapy with nadolol and topiramate on the quality of life of migraine patients. Cephalalgia 27:920–928

pubmed: 17645757 doi: 10.1111/j.1468-2982.2007.01367.x

Duan S, Ren Z, Xia H et al (2022) Association between sleep quality, migraine and migraine burden. Front Neurol 13:955298

pubmed: 36090858 doi: 10.3389/fneur.2022.955298

Tiseo C, Vacca A, Felbush A et al (2020) Migraine and sleep disorders: a systematic review. J Headache Pain 21:126

pubmed: 33109076 doi: 10.1186/s10194-020-01192-5

Gori S, Morelli N, Maestri M et al (2005) Sleep quality, chronotypes and preferential timing of attacks in migraine without aura. J Headache Pain 6:258–260

pubmed: 16362680 doi: 10.1007/s10194-005-0201-2

Raggi A, Covelli V, Leonardi M et al (2014) Difficulties in work-related activities among migraineurs are scarcely collected: results from a literature review. Neurol Sci 35(Suppl 1):23–26

pubmed: 24867830 doi: 10.1007/s10072-014-1736-2

Shapiro RE, Martin AA, Bhardwaj S et al (2023) Relationships between headache frequency, disability, and disability-related unemployment among adults with migraine. J Manag Care Spec Pharm 29:197–209

pubmed: 36705286

Shapiro RE, Hochstetler HM, Dennehy EB et al (2019) Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials. J Headache Pain 20:90

pubmed: 31464581 doi: 10.1186/s10194-019-1044-6

García-Azorín D, Moya-Alarcón C, Armada B et al (2024) Societal and economic burden of migraine in Spain: results from the 2020 National Health and Wellness Survey. J Headache Pain 25:38

pubmed: 38486155 doi: 10.1186/s10194-024-01740-3

Lombard L, Farrar M, Ye W et al (2020) A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication. J Headache Pain 21:41

pubmed: 32349662 doi: 10.1186/s10194-020-01110-9

Woodland L, Brooks SK, Webster RK et al (2023) Risk factors for school-based presenteeism in children: a systematic review. BMC Psychology 11:169

pubmed: 37221597 doi: 10.1186/s40359-023-01207-1

Leonardi M, Guastafierro E, Toppo C et al (2023) Societal and personal impact of migraine. Handb Clin Neurol 198:23–29

pubmed: 38043966 doi: 10.1016/B978-0-12-823356-6.00015-9

Snoer AH, Høst C, Dømgaard M et al (2021) Frequent or chronic migraine negatively impacts personal, social and professional life. Dan Med J 68:A08200592

pubmed: 34983726

Cerami C, Crespi C, Bottiroli S et al (2021) High perceived isolation and reduced social support affect headache impact levels in migraine after the Covid-19 outbreak: a cross sectional survey on chronic and episodic patients. Cephalalgia 41:1437–1446

pubmed: 34256651 doi: 10.1177/03331024211027568

Takahashi TT, Ornello R, Quatrosi G et al (2021) (2021) Medication overuse and drug addiction: a narrative review from addiction perspective. J Headache Pain 22:32

pubmed: 33910499 doi: 10.1186/s10194-021-01224-8

Mäki K, Vahtera J, Virtanen M et al (2008) Work stress and new-onset migraine in a female employee population. Cephalalgia 28:18–25

pubmed: 17956575 doi: 10.1111/j.1468-2982.2007.01462.x

Berardelli I, Sarubbi S, Lamis DA et al (2019) Job satisfaction mediates the association between perceived disability and work productivity in migraine headache patients. Int J Environ Res Public Health 16:3341

pubmed: 31510071 doi: 10.3390/ijerph16183341

Kuo WY, Huang CC, Weng SF et al (2015) Higher migraine risk in healthcare professionals than in general population: a nationwide population-based cohort study in Taiwan. J Headache Pain 16:102

pubmed: 26631235 doi: 10.1186/s10194-015-0585-6

Wei D, Loganathan T, Wong LP (2023) Employees of the banking sector in Guizhou Province in China: prevalence of migraine, symptoms, disability and occupational risk factors. J Headache Pain 24:52

pubmed: 37170218 doi: 10.1186/s10194-023-01591-4

Sandoe CH, Sasikumar S, Lay C et al (2019) The impact of shift work on migraine: a case series and narrative review. Headache 59:1631–1640

pubmed: 31469410 doi: 10.1111/head.13622

Xie W, Li R, He M et al (2020) Prevalence and risk factors associated with headache amongst medical staff in South China. J Headache Pain. 21:5

pubmed: 31937239 pmcid: 6961346 doi: 10.1186/s10194-020-1075-z

Suzuki K, Okamura M, Haruyama Y et al (2022) Exploring the contributing factors to multiple chemical sensitivity in patients with migraine. J Occup Health 64:e12328

pubmed: 35363938 pmcid: 9176718 doi: 10.1002/1348-9585.12328

Martins R, Large S, Russell R et al (2023) The hidden economic consequences of migraine to the UK Government: burden-of-disease analysis using a fiscal framework. J Health Econ Outcomes Res 10:72–81

pubmed: 37808457 pmcid: 10552723 doi: 10.36469/jheor.2023.87790

Begasse de Dhaem O, Sakai F (2022) Migraine in the workplace. eNeurologicalSci 27:100408

pubmed: 35774055 pmcid: 9237352 doi: 10.1016/j.ensci.2022.100408

Gerth WC, Carides GW, Dasbach EJ et al (2001) The multinational impact of migraine symptoms on healthcare utilisation and work loss. Pharmacoeconomics 19:197–206

pubmed: 11284383 doi: 10.2165/00019053-200119020-00006

Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4:353–365

pubmed: 10146874 doi: 10.2165/00019053-199304050-00006

Raggi A, Covelli V, Guastafierro E et al (2018) Validation of a self-reported instrument to assess work-related difficulties in patients with migraine: the HEADWORK questionnaire. J Headache Pain 19:85

pubmed: 30203193 pmcid: 6131677 doi: 10.1186/s10194-018-0914-7

Sakai F, Igarashi H, Yokoyama M et al (2023) Diagnosis, knowledge, perception, and productivity impact of headache education and clinical evaluation program in the workplace at an information technology company of more than 70,000 employees. Cephalalgia 43:3331024231165682

pubmed: 36967710 doi: 10.1177/03331024231165682

Vicente-Herrero T, Burke TA, Laínez MJ (2004) The impact of a worksite migraine intervention program on work productivity, productivity costs, and non-workplace impairment among Spanish postal service employees from an employer perspective. Curr Med Res Opin 20:1805–1814

pubmed: 15537481 doi: 10.1185/030079904X10151

Gerth WC, Sarma S, Hu XH et al (2004) Productivity cost benefit to employers of treating migraine with rizatriptan: a specific worksite analysis and model. J Occup Environ Med 46:48–54

pubmed: 14724478 doi: 10.1097/01.jom.0000105907.85479.3e

Riccò M, Ferraro P, Camisa V et al (2022) Managing of migraine in the workplaces: knowledge, attitudes and practices of italian occupational physicians. Medicina (Kaunas) 58:686

pubmed: 35630103 doi: 10.3390/medicina58050686

Gil-Gouveia R, Oliveira AG, Martins IP (2016) The impact of cognitive symptoms on migraine attack-related disability. Cephalalgia 36:422–430

pubmed: 26350071 doi: 10.1177/0333102415604471

Fan X, Els C, Corbet KJ et al (2016) “Decision-critical” work: a conceptual framework. J Occup Med Toxicol 11:22

pubmed: 27158256 pmcid: 4858878 doi: 10.1186/s12995-016-0115-8

DiGuiseppi CG, Johnson RL, Betz ME (2024) Migraine headaches are associated with motor vehicle crashes and driving habits among older drivers: Prospective cohort study. J Am Geriatr Soc 72:791–801

pubmed: 38133994 doi: 10.1111/jgs.18719

Agosti R (2018) Migraine burden of disease: from the patient’s experience to a socio-economic view. Headache 58(Suppl 1):17–32

pubmed: 29697152 doi: 10.1111/head.13301

Bloudek LM, Stokes M, Buse DC et al (2012) Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). J Headache Pain 13:361–378

pubmed: 22644214 pmcid: 3381065 doi: 10.1007/s10194-012-0460-7

Eltrafi A, Shrestha S, Ahmed A et al (2023) Economic burden of chronic migraine in OECD countries: a systematic review. Health Econ Rev 13:43

pubmed: 37656228 pmcid: 10472624 doi: 10.1186/s13561-023-00459-2

Husøy A, Katsarava Z, Steiner TJ (2023) The relationship between headache-attributed disability and lost productivity: 3 Attack frequency is the dominating variable. J Headache Pain 24:7

pubmed: 36782131 pmcid: 9926851 doi: 10.1186/s10194-023-01546-9

Rao GN, Kulkarni GB, Gururaj G et al (2015) The burden attributable to headache disorders in India: estimates from a community-based study in Karnataka State. J Headache Pain 16:94

pubmed: 26553066 pmcid: 4639543 doi: 10.1186/s10194-015-0574-9

Tu S, Liew D, Ademi Z et al (2020) The Health and Productivity Burden of Migraines in Australia. Headache 60:2291–2303

pubmed: 33026675 doi: 10.1111/head.13969

Steiner TJ, Jensen R, Katsarava Z (2021) Structured headache services as the solution to the ill-health burden of headache. 1. Rationale and description. J Headache Pain. 22:78

pubmed: 34289806 pmcid: 8293530 doi: 10.1186/s10194-021-01265-z

Tinelli M, Leonardi M, Paemeleire K et al (2021) Structured headache services as the solution to the ill-health burden of headache. 2. Modelling effectiveness and cost-effectiveness of implementation in Europe: methodology. J Headache Pain. 22:99

pubmed: 34425753 pmcid: 8383423 doi: 10.1186/s10194-021-01310-x

World Health Organization (2011) Atlas of headache disorders and resources in the World 2011. World Health Organization; Geneva. Available at: https://www.who.int/publications/i/item/9789241564212 . Accessed 18 July 2024

Burch R, Rizzoli P, Loder E (2018) The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies. Headache. 58(4):496–505

pubmed: 29527677 doi: 10.1111/head.13281

Friedman BW, Serrano D, Reed M et al (2009) Use of the emergency department for severe headache. A population-based study. Headache 49:21–30

pubmed: 19040677 doi: 10.1111/j.1526-4610.2008.01282.x

Katsarava Z, Dzagnidze A, Kukava M et al (2009) Primary headache disorders in the Republic of Georgia: prevalence and risk factors. Neurology 73:1796–1803

pubmed: 19933983 doi: 10.1212/WNL.0b013e3181c34abb

Ayzenberg I, Katsarava Z, Sborowski A et al (2012) The prevalence of primary headache disorders in Russia: a countrywide survey. Cephalalgia 32:373–381

pubmed: 22395797 doi: 10.1177/0333102412438977

Lisicki M, Souza MNP, de Oliveira AB et al (2022) Bridging the gaps of headache care for underserved populations: current status of the headache field in Latin America. Cephalalgia 42:1086–1090

pubmed: 35469483 doi: 10.1177/03331024221093623

Mbewe E, Zairemthiama P, Yeh HH et al (2015) The epidemiology of primary headache disorders in Zambia: a population-based door-to-door survey. J Headache Pain 16:30

pubmed: 25916334 pmcid: 4401479 doi: 10.1186/s10194-015-0515-7

Zebenigus M, Tekle-Haimanot R, Worku DK (2016) The prevalence of primary headache disorders in Ethiopia. J Headache Pain 17:110

pubmed: 27924616 pmcid: 5142157 doi: 10.1186/s10194-016-0704-z

Mauser ED, Rosen NL (2014) So many migraines, so few subspecialists: analysis of the geographic location of United Council for Neurologic Subspecialties (UCNS) certified headache subspecialists compared to United States headache demographics. Headache 54:1347–1357

pubmed: 24942840 doi: 10.1111/head.12406

Najib U, Moore M, Watson D (2019) Unique considerations for special populations in episodic migraine: the underserved. Curr Pain Headache Rep 23:9

pubmed: 30790062 pmcid: 6484839 doi: 10.1007/s11916-019-0749-1

Charleston L, Royce J, Monteith TS et al (2018) Migraine care challenges and strategies in US uninsured and underinsured adults: a narrative review, part 1. Headache 58:506–511

pubmed: 29516470 doi: 10.1111/head.13286

Charleston L, Royce J, Monteith TS et al (2018) Migraine care challenges and strategies in US uninsured and underinsured adults: a narrative review, part 2. Headache 58:633–647

pubmed: 29878343 doi: 10.1111/head.13321

Ashina M, Katsarava Z, Do TP et al (2021) Migraine: epidemiology and systems of care. Lancet 397:1485–1495

pubmed: 33773613 doi: 10.1016/S0140-6736(20)32160-7

Liu R, Yu S, He M et al (2013) Health-care utilization for primary headache disorders in China: a population-based door-to-door survey. J Headache Pain 14:47

pubmed: 23731663 pmcid: 3673891 doi: 10.1186/1129-2377-14-47

Ravishankar K (2004) Barriers to headache care in India and efforts to improve the situation. Lancet Neurol 3:564–567

pubmed: 15324725 doi: 10.1016/S1474-4422(04)00855-5

Armand CE, Borrero-Mejias C, Pace A, et al (2023) Update on Underrepresented Populations in Headache Medicine: What Is Known and Care Considerations. Pract Neurol. Available at: https://practicalneurology.com/articles/2023-may-june/update-on-underrepresented-populations-in-headache-medicine-what-is-known-and-care-considerations . Accessed 18 July 2024

Olesen J, Lekander I, Andlin-Sobocki P et al (2007) Funding of headache research in Europe. Cephalalgia 27:995–999

pubmed: 17727472 doi: 10.1111/j.1468-2982.2007.01397.x

Shapiro R, Goadsby P (2007) The long drought: the dearth of public funding for headache research. Cephalalgia 27(9):991–994

pubmed: 17727471 doi: 10.1111/j.1468-2982.2007.01396.x

Befus DR, Irby MB, Coeytaux RR et al (2018) A critical exploration of migraine as a health disparity: the imperative of an equity-oriented, intersectional approach. Curr Pain Headache Rep 22:79

pubmed: 30291549 doi: 10.1007/s11916-018-0731-3

Voloshin AG, Moiseeva IV (2021) Combined Interventional treatment of refractory chronic migraine. SN Compr Clin Med 3:1320–1326

doi: 10.1007/s42399-021-00868-6

Sacco S, Lampl C, Amin FM et al (2022) European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure. J Headache Pain 23:133

pubmed: 36224519 pmcid: 9555163 doi: 10.1186/s10194-022-01502-z

Meise R, Schwarz A, Luedtke K (2022) Effectiveness of patient education and cognitive behavioural treatment as a non-pharmacological intervention for migraine in adults – a systematic review. SN Compr Clin Med 4:197

doi: 10.1007/s42399-022-01279-x

Bassetti CLA, Endres M, Sander A et al (2022) The European Academy of Neurology Brain Health Strategy: One brain, one life, one approach. Eur J Neurol 29:2559–2566

pubmed: 35538709 doi: 10.1111/ene.15391

Steiner TJ, Husøy A, Stovner LJ (2024) GBD2021: headache disorders and global lost health – a focus on children, and a view forward. J Headache Pain 25:91

pubmed: 38831407 pmcid: 11145804 doi: 10.1186/s10194-024-01795-2

Choi BC, Pak AW (2006) Multidisciplinarity, interdisciplinarity and transdisciplinarity in health research, services, education and policy: 1. Definitions, objectives, and evidence of effectiveness. Clin Invest Med 29:351–364

pubmed: 17330451

Choi BC, Pak AW (2007) Multidisciplinarity, interdisciplinarity, and transdisciplinarity in health research, services, education and policy: 2. Promotors, barriers, and strategies of enhancement. Clin Invest Med 30:E224–E232

pubmed: 18053389 doi: 10.25011/cim.v30i6.2950

Choi BC, Pak AW (2008) Multidisciplinarity, interdisciplinarity, and transdisciplinarity in health research, services, education and policy: 3. Discipline, inter-discipline distance, and selection of discipline. Clin Invest Med 31:E41–E48

pubmed: 18312747 doi: 10.25011/cim.v31i1.3140

Sun Y, Livan G, Ma A et al (2021) Interdisciplinary researchers attain better long-term funding performance. Commun Phys 4:263

doi: 10.1038/s42005-021-00769-z

Hallmarks of primary headache: part 1 - migraine.

Journal

Informations de publication

Résumé

Sections du résumé

Identifiants

Types de publication

Langues

Sous-ensembles de citation

Pagination

Informations de copyright

Références

Auteurs

Articles similaires

Classifications MeSH